Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
CURRICULUM VITAE
Name:
Jan-Åke Gustafsson, M.D., Ph.D.
Date of Birth:
August 4, 1943
Education:
Ph.D., Dept of Chemistry, Karolinska Institutet, 1968
M.D., Karolinska Institutet, 1971
Career/Academic Appointments:
1964
1971
1976
1978
1979
2006-present
Bachelor of Medicine, Karolinska Institutet, Stockholm
Associate Professor in Chemistry, Karolinska Institutet
Professor of Chemistry, Karolinska Institutet
Professor of Chemistry, University of Gothenburg
Professor of Medical Nutrition and Chairman of the Dept of Medical
Nutrition, Huddinge University Hospital, Karolinska Institutet
Professor of Medical Nutrition and Chairman of the Dept of Biosciences and
Nutrition, Karolinska Institutet
Administrative Positions:
1985
1987
1979 – 1991
2004-present
Director of the Center for Biotechnology, Huddinge University Hospital,
Karolinska Institutet
Founder of KaroBio AB (a campus-situated biotechnology company
sponsored by pension and governmental funds with about 80 employees).
Project leader of the Swedish EPA research program on Air Pollution in
Urban Areas
Coordinator for the EU funded CASCADE Network of Excellence
Professional Honors & Recognition
A) International/National/Regional
2008 Foreign Member Finnish Scientific Society
2008 EMD Serono President’s Distinguished Lecture. Annual Meeting of the Society for
Gynecological Investigation, San Diego.
2008 International Member American Philosophical Society
2005 Descartes Research Prize for excellence in scientific collaborative research
2005 2nd Ernst Knobil Memorial Lecture, San Diego, USA
2004 Medal from Biomedicum Helsinki
2004 Bristol-Meyers Squibb/Mead Johnson Award for Nutrition Research
2003 FEBS Lectureship Datta Award
2003 McDowell Lecture in Physiology, King’s College, London, U.K.
2002 Commandeur dans l’Ordre des Palmes Académiques
2002 Foreign Honorary Member of the US National Academy of Sciences
2002 Chairman of the Nobel Assembly of the Karolinska Institutet
2002 Fred Conrad Koch Award (Endocrine Soceity USA)
2001 The AF Group Prize for the creation of Novum Research Park
2001 Lorenzini Gold Medal, Lorenzini Foundation
2001 Vice chairman of the Nobel Assembly of the Karolinska Institutet
1
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
2000
2000
2000
2000
2000
2000
1999
1999
1998
1998
1998
1997
1994
1992
1992
1992
1990
1986
1986
1983
1982
One of ISI Top 258 Researchers in Biology & Biochemistry
Garvan International Fellow
Burroughs Wellcome Fund Lecture
Foreign Honorary Member of the American Academy of Arts and Sciences
European Medal, British Society for Endocrinology
Curt Nicolin’s Prize for Achievements for the Development of South Stockholm
Medal of the IngaBritt and Arne Lundberg’s Research Foundation
Fogarty Scholar NIH
Adjunct Member of the Nobel Committee of the Karolinska Institutet
The Söderberg Prize in Medicine
Member of the Swedish Academy of Engineering Sciences
Member of the Swedish Academy of Sciences
Gregory Pincus Medal and Award, Worcester Foundation
Keith Harris Lecture, Australian Endocrine Society, Adelaide
The Anders Jahre Prize, Oslo
Medal from Collège de France, Paris
Honorary Member of the American Society for Biochemistry and Molecular Biology
Honorary Member of the Japanese Biochemical Society
Member of the Nobel Assembly of the Karolinska Institutet
The Fernström Prize of the Karolinska Institutet
The Svedberg Prize in Chemistry, Stockholm
B) University
2008
2008
2007
2004
2003
2003
2002
2000
1995
1991
1987
Honorary Professor at the Beijing Normal University
Honorary doctorate in Medicinal and Pharmaceutical Chemistry at the University of
Milan
Honorary Professor at the University of Chongquin, China
Guest Professor at the University of Science and Technology of China, Hefei
J.G. Moore Visiting Professor, UCLA, USA
Marius Tausk Visiting Professor at the Leiden University Medical Centre (LUMC)
Burroughs Wellcome Fund Visiting Professor in the Basic Medical Sciences at the
University of Texas Medical Branch School of Medicine
Center for Bioenvironmental Research Distinguished Visiting Professor, Tulane
University, New Orleans
Sterling Visiting Professor, University of Pennsylvania, Philadelphia
Consultant to The Rockefeller University Hospital
Adjunct Full Professor at the Department of Cell Biology, Baylor College of
Medicine, Houston, Texas
Has participated in several international reviewing panels, e.g.:
1995 Chairman of a board evaluating the Center for Biotechnology, University of Oslo.
1994 Member of a board evaluating the Center for Biotechnology, Helsinki.
1991 As chairman of a board evaluating the Norwegian Biotechnology Program.
2
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
Peer Review Groups/Grant Study Sections:
2007 Member of the LTA (LAM Treatment Alliance) SAB (Scientific Advisory Board, Boston.
2007 Member of the IRB Barcelona External Advisory Board.
2007 Member of the selection committee for The King Faisal International Prize in Science.
2005-2007 Member of the International Academic Advisory Committee (IAAC), Hefei,
Peoples’s Republic of China.
1995-Member of the International Advisory Board of the WHO Center in Oulu.
Journal Service:
Member, currently and/or previously, of the editorial board or similar position in Steroids, The
Journal of Steroid Biochemistry and Molecular Biology, Molecular Endocrinology, Breast Cancer
Research and Treatment, The Prostate, Anticancer Research, Japanese Journal of Cancer
Research, Journal of Molecular Medicine, Molecular Pharmacology, Cell Metabolism,
Experimental Biology and Medicine and the International Journal of Oncology.
Board Certification:
Elected Councillor/Board Member of the Swedish Medical Research Council during the 1990´ies
(for 6 years).
Member of the Research Board of the Swedish Cancer Society during the 1980´ies and
1990´ies (for 6 years).
Member of the Research Board of the Swedish Council for Planning and Coordination of
Research during the 1980´ies and 1990´ies (for 6 years).
Has been member of the Faculty Board of the Karolinska Institutet and regularly carries out
various assignments for the President’s Office of the Karolinska Institutet.
Awards Committee Member, Endocrine Society, USA 2002-06.
Elected Member of Council (Board) of Endocrine Society, USA, 2007 –
Organisation of International conferences:
1983
Nobel symposium “Steroid hormone receptors: Structure and function”.
1988
2nd CBT Symposium “The steroid/thyroid hormone receptor family and gene regulation”.
1993
5th CBT Symposium “Intracellular hormone receptors and ligand-dependent transcriptional
regulation”.
1995
7th CBT Symposium “Nuclear orphan receptors: Novel regulators in physiology and
pathology”.
1995
EMBO Workshop; Structure and Function of Steroid and Nuclear Receptors, Alghero,
Sardinia, Italy.
1997
9th CBT (Centre for Biotechnology) Symposium “Steroid and orphan nuclear receptors”,
Huddinge, Sweden.
3
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
1999
Nobel symposium “Estrogens and women’s health – benefit or threat?”, Karlskoga,
Sweden.
1999
EMBO Workshop; Steroids and Nuclear receptors, Villefranche, France.
2000
FEBS Advanced Study Institute, International Summer School on “New Dimensions in the
Regulation of Gene Expression, Island of Spetses, Greece.
2000
10th CBT symposium “Nuclear receptors in health and disease”, Huddinge, Sweden.
2001
EMBO Workshop on Nuclear Receptor Structure and Function, Erice, Italy.
2002
“Nuclear Receptors 2002”, A joint International Symposium arranged by CBT, Karolinska
Institutet, in collaboration with the Summer University of Southern Stockholm, Huddinge,
Sweden.
2003
EMBO Conference, Biology of Nuclear Receptors, Villefranche-sur-Mer, France.
2003
Nobel Conference No 40: “Transcriptional control of lipid homeostasis”, Huddinge, Sweden.
2003
FEBS Advanced Study Institute, International Summer School on “From Transcription to
Physiology: Regulation of Gene Expression and Protein Function in an Integrated Context”,
Island of Spetses, Greece.
2004
“Nuclear Receptors 2004” An International Symposium arranged by CBT, Karolinska
Institutet, Huddinge, Sweden.
2006
“Nuclear Receptors 2006” An International Symposium arranged by CBT, Karolinska
Institutet, Huddinge, Sweden.
2007
Spetses Summer School on “Nuclear Receptor Signaling: From Molecular Mechanisms to
Integrative Physiology”, Island of Spetses, Greece.
2008
Nobel Conference No 52 on “Recent advances in understanding estrogen signaling: From
molecular insights to clinical implications”, Sånga-Säby, Stockholm, Sweden.
Patents, Softwares, Databases
Estrogen receptor -based hypertension treatment and assay.
Patent No: GB 2374412
Estrogen receptors and their ligands for treating obesity and lowering lipoprotein levels
Patent No: US 2002151732
Cloning, characterization and pharmaceutical use of a mammalian nuclear receptor coactivator
RAP250.
Patent No: US 2002151477
Estrogen receptor beta (ER) agonists for use in cancer treatment.
Patent No: GB 2361642
4
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
Method of estrogen receptor isoform detection via immunostaining and correlation with breast
cancer.
Patent No: GB 2361769
Cancer treatment and prognosis involving HES-1 protein.
Patent No: WO 2001062792
Estrogen receptor  agonists and antagonists for the treatment of growth or bone mineral
density disorders.
Patent No: WO 2000076529
Osteoporosis treatment with an estrogen receptor  antagonists.
Patent No: WO 2000061230
Estrogen receptor ER  ligands for Vasculoprotectors.
Patent No: WO 2000001716
Differential activation of estrogen receptors ERand ER at ap1 sites.
Patent No: WO 9911760
Molecular cloning, cDNA sequences, and therapeutic uses of mammalian estrogen receptor.
Patent No: WO 9709348
OR-1 orphan receptors belonging to the nuclear receptor family.
Patent No: WO 605300
Other Activities:
Has participated in the supervision of 96 Ph.D. students to the presentation of their thesis.
Has supervised 129 postdocs/visiting scientists.
Has 1319 peer-reviewed publications. Can be sent upon request.
Has so far been cited 61 912 times.
H-index: 108
Grant History:
A)
Current Grants
Agency:
I.D.#
Title:
Swedish Research Council
701192301
“The oxysterol receptors LXRα and LXRβ in pathophysiology and molecular
mechanisms of metabolic, autoimmune and neurodegenerative disorders”
P.I.:
Jan-Åke Gustafsson, M.D., Ph.D., Professor
Percent effort: 15%
Direct costs per year: SEK 1,700,000/ $240,452
Total costs for project period: SEK 5,100,000/ $721,358
Project period: 01/01/2008 – 12/31/2010
Agency:
Swedish Cancer Society
5
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
I.D.#
07 0090
Title:
“Estrogen receptor beta and estrogen related forms of cancer”
P.I.:
Jan-Åke Gustafsson, M.D., Ph.D., Professor
Percent effort: 20%
Direct costs per year: SEK 2,000,000/ $283,006
Total costs for project period: SEK 6,000,000/ $849,017
Project period: 01/01/2007 – 12/31/2009
Agency:
I.D.#
Title:
EU
FOOD-CT-2004-506319
CASCADE “Chemicals as contaminants in the food chain: An NOE for
research, risk assessment and education”
P.I.:
Jan-Åke Gustafsson, M.D., Ph.D., Professor
Percent effort: 15%
Direct costs per year: EUR 195,810:80/ $265,030
Total costs for project period: EUR 979,054/ $1,325,150 (our part)
Project Period: 02/01/2004 – 01/31/2009
Agency:
EU
I.D.#
LSHM-CT-2005-518245
Title:
EWA “Estrogens and women ageing”
P.I.:
Adriana Maggi, Ph.D., Professor
Role on Project: Partner
Percent Effort: 5%
Direct costs per year: EUR 70,000 / $94,745
Total costs for the project period: EUR 210,000/ $284,235 (our part)
Project Period: 01/01/2006 – 12/31/2008
Agency:
EU
I.D.#
LSHM-CT-2005-018652
Title:
CRESCENDO “Consortium for Research into Nuclear Receptors in
Development and Aging”
P.I.:
Barbara Demeneix, Ph.D., D.Sc., Professor
Role on Project: Partner
Percent Effort: 5%
Direct costs per year: EUR 99,240/ $181,804
Total costs for the project period: EUR 496,200/ $909,020 (our part)
Project Period: 03/01/2006 – 02/28/2011
Agency:
I.D.#
Title:
EU
FOOD-CT-2005-513991
PIONEER “Puberty onset – influence on nutritional, environmental and
endogenous regulators”
P.I.:
Sari Mäkelä, M.D., Ph.D., Professor
Role on Project: Partner
Percent Effort: 5%
Direct costs per year: EUR 54,400/ $73,630
Total costs for the project period: EUR 163,200/ $220,890 (our part)
Project Period: 03/01/2005 – 02/28/2008
Agency:
KaroBio AB
6
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
I.D.#
Cooperation grant
Title:
“Orphan Receptors”
P.I.:
Jan-Åke Gustafsson, M.D., Ph.D., Professor
Percent effort: 10%
Direct costs per year: SEK 2,000,000 - SEK10,000,000/$ 282,885 - $1,414,427
Total costs for project period: SEK 77,741,725/$10,996,000
Project period: 1987 -
B)
Past Grants*
*Professor Gustafsson has been a grant holder for the last 35 years. It is an almost impossible
work to list them all. This shows the last five years of past grants.
Agency:
I.D.#
Title:
Swedish Research Council
K2002-03X-02819-33
“Mechanism of action of nuclear receptors: biological function of the orphan
receptors LXRalpha and LXRbeta”
P.I.:
Jan-Åke Gustafsson, M.D., Ph.D., Professor
Percent effort: 15%
Direct costs per year: SEK 1,400,000/ $198,104
Total costs for project period: SEK 8,400,000/ $1,188,624
Project period: 01/01/2002 – 12/31/2007
Agency:
Swedish Cancer Society
I.D.#
05 0212
Title:
“The role of estrogen receptor in cancer”
P.I.:
Jan-Åke Gustafsson, M.D., Ph.D., Professor
Percent effort: 20%
Total costs for project period: SEK 6,900,000/ $976,369
Project period: 01/01/2004-12/31/2006
Agency:
I.D.#
Title:
EU
FOOD-CT-2003-506143
DEVNERTOX “Toxic threats to the developing nervous system: In vivo and in
vitro studies on the effects of mixture of neurotoxic substances potentially
contaminating food”
P.I.:
Sandra Ceccatelli, M.D., Ph.D., Professor
Role on project: Partner
Percent effort: 5%
Total costs for project period: EUR 240,000/ $324,840 (our part)
Project period: 12/01/2003-11/30/2006
Agency:
EU
I.D.#
QLK4-CT-2002-02528
Title:
BONETOX “Bone development and homeostasis-critical targets in toxicology”
P.I.:
Helen Håkansson, Ph.D., Professor
Role on project: Partner
Percent effort: 5%
Total costs for project period: EUR 263,813/ $357,071 (our part)
Project period: 01/01/2003-12/31/2006
7
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
Agency:
I.D.#
Title:
EU
QLK4-CT-2002-02221
EDERA “Development and implementation of new in vivo and in vitro systems
for the characterization of endocrine disrupters”
P.I.:
Adriana Maggi, Ph.D., Professor
Role on project: Partner
Percent effort: 5%
Total costs for project period: EUR 172,500/ $233,479 (our part)
Project period: 01/01/2003-06/30/2006
Participated in the supervision of the following Ph.D. and M.Sci students to the
presentation of their theses
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
Håkan Eriksson: Studies on the metabolism of steroid hormones in rat liver. Thesis, 1971.
Sven A. Gustafsson: Sexual differentation of corticosteroid metabolism in the rat. Thesis,
1974.
Åke Stenberg: Mechanisms of sexual differentiation of steroid metabolism in rat liver. Thesis,
1974.
Magnus Ingelman-Sundberg: Hepatic metabolism of steroid sulphates with special reference
to cytochrome P-450-catalyzed reactions. Thesis, 1975.
Åke Pousette: Studies on the control of androgen responsiveness in rat. Thesis, 1976.
Örjan Wrange: Studies on the glucocorticoid receptor in rat liver and the estradiol receptor in
human breast cancer. Thesis, 1977.
Paul Skett: Hypophyseal control of hepatic steroid metabolism in the rat. Thesis, 1977.
Anders Berg: Studies on cytochrome P-450-dependent steroid hydroxylations in mammalian
and bacterial systems. Thesis, 1978.
Peter Ekman: Steroid receptors in the human prostate. Thesis, 1978.
Jan Carlstedt-Duke: Studies on two hepatic intracellular receptor proteins in the rat: The
glucocorticoid receptor and the 2,3,7,8-tetrachlorodibenzo-p-dioxin receptor. Thesis, 1979.
Björn Forsgren: Studies on a major protein in the ventral prostate of the rat that interacts with
metabolites of estramustine phosphate and related steroid-cytostatic complexes. Thesis,
1979.
Erik Dahlberg: Studies on steroid hormone receptors in rat skeletal muscle. Thesis, 1980.
Zhao-Ying Yu: Studies of steroid hormone receptors in brain. Thesis, 1981.
Gunnar Norstedt: Regulations of prolactin and estrogen receptors in rat liver. Thesis, 1981.
Tiiu Hansson: Studies on hepatic steroid metabolism in rainbow trout, Salmo gairdneri.
Thesis, 1981.
Livia Alm: The effect of fermentation on nutrients in milk and some properties of fermented
liquid milk products. Thesis, 1982.
Rune Toftgård: Xylene, an inducer of hepatic cytochrome P-450 and xenobiotic
biotransformation in the rat. Thesis, 1982.
Joseph J. Rafter: Role of the intestinal microflora in the formation of sulphur-containing
conjugates of xenobiotics. Thesis, 1982.
Tapio Haaparanta: Isolation of subcellular fractions from the rat ventral prostate and
characterization of prostacic cytochrome P-450. Thesis, 1983.
Agneta Mode: Growth hormone - a regulator of the sexually differentiated steroid metabolism
in rat liver. Thesis, 1983.
Tönu Saartok: Steroid receptors as prediction of direct hormonal response in human and
rabbit skeletal muscle. Thesis, 1983.
8
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
Sam Okret: Immunochemical studies on glucocorticoid receptor structure and function.
Thesis, 1983.
Lorenz Poellinger: Characterization of the receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in
rat liver. Thesis, 1985.
Catriona MacGeoch: Characterization and growth hormone regulation of sexually
differentiated cytochrome P-450 isozymes in rat liver. Thesis, 1986.
Johan Lund: Methyl sulfone metabolites of polychlorinated biphenyls: studies on the
mechanism of accumulation in lung. Thesis, 1986.
Ann-Charlotte Wikström: Production and use of monoclonal antibodies against the
glucocorticoid receptor. Thesis, 1986.
Agneta Blanck: The hypothalamo-pituitary-liver axis - a possible determinant of sex
differences in chemical hepatocarcinogenesis in the rat? Thesis, 1987.
Peter Söderkvist: Studies on regulation and enzymatic activity of drug-induced cytochrome P450 in rat ventral prostate. Thesis, 1987.
Mikael Gillner: Studies on the receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat.
Thesis, 1988.
Lennart Möller: 2-Nitrofluorence, in vivo metabolism and assessment of cancer risk of an air
pollutant. Thesis, 1988.
Mikael Brönnegård: Studies on the structure and function of the human and the rat
glucocorticoid receptor. Thesis, 1988.
Bolette Husman: Characterization of the somatogenic receptor in rat liver. Thesis, 1988.
Sam Törnquist: Uptake, metabolism and DNA-binding of the chemical carcinogens benzo(a)pyrene and 2-nitrofluorene in the rat lung. Thesis, 1989.
Marc Denis: The non-activated glucocorticoid receptor: structure and activation. Thesis, 1989.
Lars-Arne Haldosén: Characterization of the prolactin receptor in rat liver. Thesis, 1989.
Anders Berkenstam: Estrogen and progesterone receptors in human breast cancer cells:
studies on mechanisms for steroid dependent versus constitutive gene expression. Thesis,
1989.
Eva Övervik: Formation and biological effects of cooked-food mutagens. Thesis, 1989.
Yu Dong: Transcriptional and post-transcriptional regulation of gene expression: Studies on
glucocorticoid receptor and alcohol dehydrogenase. Thesis, 1990.
Pia Lindeskog: Effects of diet on rat small intestinal cytochrome P-450 IA1. Thesis, 1990.
Scott Cuthill: The mechanism of action of the dioxin receptor. Thesis, 1990.
Gunnar Johansson: Effects of a shift from a mixed diet to a lactovegetarian diet on some
colon cancer associated characteristics. Thesis , 1990.
Karin Dahlman-Wright: DNA-binding by the glucocorticoid receptor: a structural and functional
analysis. Thesis, 1991.
Ann Lidbeck: Studies on the impact of Lactobacillus acidophilus on human microflora and
some cancer-related intestinal ecological variables. Thesis, 1991.
Carol Cairns: Mechanisms and role of DNA-binding in steroid hormone receptor action.
Thesis, 1993.
Gunnar Akner: Localization of glucocorticoid receptor (GR) and heat shock protein Mr 90,000
(Hsp90) in mammalian cells. Thesis, 1993.
Maria Strömstedt: Characterization of cytochrome P450 in rat ventral prostate and brain.
Thesis, 1993.
Olof Andersson: Structure and function of a Clara cell-specific, PCB-binding protein. Thesis,
1993.
Per-Erik Strömstedt: Molecular analysis of glucocorticoid receptor-hormone interaction.
Thesis, 1993.
Anna Wilhelmsson: Mechanism of activation of the dioxin receptor. Thesis, 1993.
9
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
Wilhelm Cairns: A study of mechanisms involved in the control of glucocorticoid receptor
function. Thesis, 1993.
Anders Ström: Cloning, characterization and regulation of CYP2C genes expressed in rat
liver. Thesis, 1994.
Johanna Zilliacus: Structural determinants of DNA-binding specificity by the glucocorticoid
receptor. Thesis, 1994.
Petra Tollet: Growth hormone signal transduction and regulation of CYP2C12 expression in
primary rat hepatocytes. Thesis, 1995.
Carol Soontjens: Ligands for nuclear receptors development and application of methods for
identification. Thesis, 1995.
Dezhong Liao: Hormonal regulation of sex differentiated liver carcinogenesis in the rat.
Thesis, 1996.
Stefan Westin: Regulation of cytochrome P4502C7: Effects of growth hormone and vitamin A.
Thesis, 1996.
Marika Kleman: Regulation of dioxin receptor function by procarcinogenic food-derived
heterocyclic amines and indolocarbazoles. Thesis, 1996.
Kaj Grandien: The estrogen receptor gene; promoter organization and expression. Thesis
1996.
Magnus Nord: Regulation and function of the Clara cell secretory protein. Thesis 1997.
Jacqueline McGuire: Mechanism of conditional regulation of the bHLH/PAS dioxin receptor.
Thesis, 1997.
Yang Yang: The in vivo metabolism of benzo[a]pyrene studied by chromatography in
combination with mass spectrometry. Thesis, 1997.
Tova Almlöf: Gene regulation by the glucocorticoid receptor: Post-DNA binding mechanisms
of transcriptional activation. Thesis, 1997.
Heike Hellmold: Toxicological and endocrinological aspects of cytochrome P450 in breast
and lung. Thesis, 1998.
Thomas Meyer: Mechanism of conditional repression of human osteocalcin gene activity by
glucocorticoids. Thesis, 1998.
Tony Pircher: Regulation of STAT5 activity by growth hormone. Thesis, 1998.
Annika Wallberg: Chromatin remodeling complexes involved in gene activation by the
glucocorticoid receptor. Thesis, 1999.
Ulrika Lind: Functional analysis of ligand recognition by the glucocorticoid receptor. Thesis,
2000.
Katarina Pettersson: Signal transduction via estrogen receptors (ERs) and estrogen receptorrelated receptors (ERRs). Thesis, 2000.
Thomas Barkhem: Molecular mechanisms of estrogen/antiestrogen action. M.Sci. thesis,
2000.
Johan Lidén: Repression of transcription factor NF-B by glucocorticods. A molecular
mechanism for their anti-inflammatory and immuno-modulatory effects. Thesis, 2000.
Eva Hedlund: Cytochrome P450 in the rat brain: Characterization and regulation. Thesis,
2000.
Tobias Cassel: Transcriptional regulation of differentiation markers in the distal lung
epithelium – A role for C/EBP factors. Thesis, 2001.
Sara Windahl: Functions of estrogen receptor  in the metabolism of rodent bone. Thesis,
2001.
Anette Wärnmark: Molecular mechanisms of gene activation by nuclear receptors and their
associated coregulators. Thesis, 2001.
Lotta Johansson: Studies on the atypical orphan receptor SHP. Thesis, 2001.
Zhang Weihua: Estrogen receptor  in the urogenital tract of both male and female. Thesis,
2002.
10
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
77.
78.
Tomas Barkhem: Molecular Mechanisms of estrogen and antiestrogen action. Thesis, 2002.
Hanna Helander: Studies on growth hormone regulation of the CYP2C12 gene in rat liver.
Thesis, 2003.
79. Christina Widén: Studies of glucocorticoid receptor interacting proteins. Licentiate thesis,
2003.
80. Anastasios E. Damdimopoulos: Identification and functional characterization of novel
thioredoxin systems. Thesis, 2003.
81. Hanne Olsen: STAT5A expression and regulation in mammary epithelial cells. Thesis, 2004.
82. Knut R. Steffensen: Putative functions of the liver X receptors in metabolic disorders. Thesis,
2004.
83. Malin Hedengran Faulds: Estrogen receptor signaling in mammary epithelial cells. Thesis,
2004.
84. Elin Holter: Modulation of nuclear receptor activity by a unique class of corepressors. Thesis,
2004.
85. Ann Båvner: Molecular mechanisms of transcriptional repression by the orphan receptor
SHP. Thesis, 2005.
86. Waffa Osman: Functional interaction between the glucocorticoid receptor and the proteins
RIP140 and GANP. Masters thesis, 2005.
87. Christina Widén: Studies of glucocorticoid receptor interacting proteins. Thesis, 2005.
88. Nina Heldring: Molecular basis of estrogen receptor antagonism. Thesis, 2006.
89. Sandra Andersson: Nuclear receptor functions in the central nervous system: clues from
knockout mice. Thesis, 2006.
90. Otabek Imamov: Role of estrogen receptor beta in mouse ventral prostate with referencies to
human prostatic diseases. Masters thesis, 2006.
91. Maria Nilsson: Estrogen and liver X receptors in human disease. Thesis, 2006.
92. Hui Gao: Estrogen signaling in metabolic disease; A functional genomics approach. Thesis,
2006.
93. Waffa Osman: Modulating of nuclear receptor function by interacting proteins. Thesis, 2007.
94. Otabek Imamov: Role of estrogen receptor beta in mouse prostate and bladder with
references to human diseases. Thesis, 2007.
95. Lovisa Lundholm: Molecular mechanisms of estrogen action in relation to metabolic disease.
Thesis, 2007.
96. Andrea Morani: Role of estrogen receptor beta in Epithelia lacking estrogen receptor alpha
expression. Thesis, 2008.
97. Patrick Müller: Hormonal regulation of HES-1 in breast cancer cells. Thesis, 2008.
98. Linda Aronsson: Microbial regulation of PPARγ: Nuclear receptor networks important for
colonic homeostasis. Thesis, 2008.
99. Johan Hartman: Antiproliferative action of estrogen receptor  and HES-1 in breast cancer.
Thesis, 2008.
100. Hyun-Jin Kim: LXR and aromatase knock-out mice: Animal models providing insight into
human diseases. Thesis, 2009.
Postdocs and visiting scientists with Jan-Åke Gustafsson
Name
From
To
1.
2.
3.
4.
1970–1972
1971
1979
1979-1982
2 years
1 year
1 year
3 years
Cedric Shackleton
René-Jean Begue
Dominique Bression
Marek Snochowski
11
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
5. Rabinder Kurl
before 1981
2 years
6. Peter Hall
7. Jim Halpert
8. Edward Morgon
9. Rita Hannah
10. Gillian Howell
before 1981
1982-1984
1983–1987
1983
1984
1 year
2 years
4 years
1 year
1 year
11. Tony Wright
12. Constanze Bonifer
13. Ian Callard
14. Paolo Rossini
15. Janet Hapgood
1985–1990
1986–1987
1987
1985
1987
5 years
1 year
1 year
1 year
1.5 years
16. John Robertson
17. Grant Mason
18. Peter Zaphiropoulos
19. Hirotoshi Tanaka
20. Catherine Legraverend
870101
880101
880101
890616
890801
901231
920228
931215
910630
930731
21. Iain McEwan
22. Sarah Ben-Or
23. Chris Liddle
24. T Nemoto
25. Y Ohara Nemoto
891001
900101
900301
1988-1989
1988-1989
970131
901231
911031
2 years
2 years
26. Shin-Ichi Hayashi
27. Kevin Johnson
28. Katerine Gearing
29. Martin Göttlicher
30. Anke van Eekelen
1990-1991
1990
900401
910101
910201
2 years
1 year
930924
940221
920131
31. Eric First
32. Murray Whitelaw
33. Michèle Teboul
34. Roger Martin
35. Arvydas Kanopka
910401
910401
920115
920127
920215
940930
951231
941231
931231
921215
36. Adrian Wyss
37. Helen Osipova
38. Henry Barnes
39. Olivier Lahuna
40. Shigetaka Yoshida
920609
920801
920819
920909
930301
950630
940228
940831
960731
950228
41. Franck Delaunay
42. Anja Crickmore
43. Franziska Wiebel
44. Jaqueline Ford
930601
960117
930607
931101
931108
951015
980228
941101
951031
961031
45. Katrin Hecht
940112
951231
12
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
46. Carlos Bocos
47. Craig Rowlands
48. Eckardt Treuter
49. Greg Lamb
940117
940117
940413
940708
951231
951231
still
960630
50. Chris Corton
51. Dorothee Feltkamp
52. Siegfried Alberti
53. Hebe Guardiola-Diaz
54. Leandro Fernandez
940713
940801
940801
940819
940831
951031
990531
990228
960818
961013
55. George Kuiper
56. Alfin Vaz
57. Paula Lapinskas
58. Diane DePalo
59. Christine Sadek
941212
1995
950417
951002
951118
980901
6 months
960229
960229
040331
60. Stéphan Jalaguier
61. Martin Holtmann
62. Jörg Leers
63. Antonio Miranda
64. Markko Pelto-Huikko
960213
960311
960401
960613
960801
990630
970131
021031
041231
980731
65. Francis Simon
66. Ralf Meyer
67. Jane Sohn-Thomsen
68. Sari Mäkelä
69. Kenichi Mikitani
“
“
960916
961001
961201
1997
970121
000515
970630
970801
040630
030531
990531
050630
70. Michel Tujague
71. Giulia Friso
72. José Pedrajas-Cabrero
73. Francoise Caira
74. Moraima Zelada
970414
970513
970609
970701
970915
070531
980131
990630
990610
001231
75. Jeanette Webster
76. Gordon Jamieson
77. Gertrud Schuster
78. Gary Faulds
79. Elwood Jensen
980301
980415
980602
980608
980122
010430
990228
040630
000430
010331
80. Naoya Arai
81. Adrian Allan
82. Anni Wärri
83. Kazuhito Mizuki
84. Domingo N-Bosch
980615
980901
980901
981216
990118
990930
000831
990831
011031
000430
85. Jerzy Adamski
86. Shigehira Saji
87. Guojun Cheng
990301
990414
990914
000229
010131
090216
13
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
88. Zhao Bian
89. Ling Wang
991001
991020
020731
030228
90. Cesare Patrone
91. Silke Kietz
92. Carola Förster
93. Michio Otsuki
94. Hideki Sakaguchi
000405
000602
000703
000801
000808
010731
030531
030430
030920
021231
95. Chunyan Zhao
96. Thomas Stulnig
97. Alberto Jiménez Garcia
98. Jian Lu
99. Gil-jin Shim
010101
010302
010702
010816
010901
still
020331
030630
020815
051231
100. Andrew Sakko
101. Kirsten Remen
102. Qing Hong Zhang
103. Jason Matthews
104. Didier Bouton
010903
010915
011001
011010
011030
021231
still
020630
060413
050630
105. Sabyasachi Sanyal
106. Yungshang Piao
107. Yoko Omoto
108. Yutaka Shoji
109. Luisa Helguero
020520
020604
020729
020906
030203
070331
040531
still
040817
still
110. Jinghong Wan
111. Thomas Schwend
112. Xiaohua Lou
113. Osamu Hiraike Wada
114. Sebastian Lewandowski
030314
040826
040901
050321
050810
050313
080831
still
070228
080229
115. Marion Korach-André
116. Amena Archer
117. Xiaotang Fan
118. Shuyang Yu
119. Konstantin Yakimchuk
050905
060109
060203
060901
060918
still
still
080801
070331
090101
120. Punga Tanel
121. Ivan Nalvarte
122. Yawen Liu
123. Rodrigo Barros
124. Knut Steffensen
061001
061101
070122
070305
070301
070114
still
080118
090201
still
126. Paloma Alonso-Magdalena070604
127. Nobuhiro Sugiyama
070701
128. Nicolas Venteclef
080107
129. Tassos Damdimopoulos 080211
130. Yongwen Chen
080925
090101
090401
still
still
090201
14
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
Scientific Leadership Profile:
As is evident from other material presented in this application, we have contributed significantly
to the development of the field of nuclear receptors since the 1970´ies. Our discoveries include
early demonstration of the three-domain structure of nuclear receptors, specific binding of
nuclear receptors to DNA, discovery of steroid response element, cloning of the first nuclear
receptor fragment, first determination a 3-D structure of a nuclear receptor (the DNA binding
domain of the glucocorticoid receptor), discovery of the first physiological ligand of a nuclear
receptor (fatty acids for the peroxisome proliferator activated receptor alpha), discovery of liver
X receptor beta (LXRβ), discovery of estrogen receptor beta (ERβ) and unravelling of some of
their their functions.
All of the above achievements represent breakthrough events which have significantly impacted
upon both the nuclear receptor field as well as neighbouring disciplines. For instance, our
demonstration of specific DNA binding of the glucocorticoid receptor helped to develop the
enhancer concept and initiated a more molecular phase in the field of nuclear receptors. Our
finding of fatty acids as activators of peroxisome proliferator activated receptor alpha helped to
bring nutrition closer to endocrinology, thereby being perhaps one of the first examples of
molecular nutrition research. Our discovery of ERβ has meant a paradigm shift in our
understanding of estrogen signaling, has stimulated pharmaceutical science to develop novel
ER isoform specific drugs with broad indications for use against various diseases and has had
major impact on the toxicological field of endocrine disruption with particular emphasis on the
risk assessment of environmental exposure to xenoestrogens.
Our research achievements have been very well received by the scientific community. I have so
far been cited 59 941 times. I have received numerous international awards and distinctions, e g
Fogarty Scholar NIH 1999; Foreign Honorary Member of the American Academy of Arts and
Sciences 2000; European Medal, British Society for Endocrinology 2000; Lorenzini Gold Medal,
Lorenzini Foundation 2001; Foreign Honorary Member of the US National Academy of Sciences
2002; Fred Conrad Koch Award (Endocrine Society USA) 2002; Bristol- Meyers Squibb/Mead
Johnson Award for Nutrition Research 2004; Descartes Research Prize for excellence in
scientific collaborative research 2005; Honorary Professor at the University of Chongquin, China
2007; Honorary doctor in Medicinal and Pharmaceutical Chemistry at the University of Milan
2008; Honorary Professor at the University of Beijing 2008.
As is evident from other parts of this application we have obtained substantial funding from EU,
eg for the NoE CASCADE (for which I am coordinator) as a further sign of the good international
reputation of our research group.
All our scientific work has been done in parallel with our building up of the medical research
centre, Novum, at the South Campus of the Karolinska Institutet in Huddinge in South
Stockholm. The vision of this endeavour has been the integration of preclinical research (e g our
own work) and clinical research in a new type of academic environment with small physical
distances between the different competencies. With this goal in mind we created Novum, a new
building encompassing approximately 500 000 sq feet of research laboratories and offices, side
by side with Huddinge University Hospital at South Karolinska Institutet. As the first tenants, we
moved into Novum in 1990. This was about ten years after our research group had moved
(1981) from the North Campus of the Karolinska Institutet in Solna to the South Campus. During
15
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
these ten years (1981–1990) we established three research centres, Centre for Biotechnology,
Centre for Nutrition and Toxicology and Centre for Structural Biochemistry, financed by the
Stockholm County Council, i.e. the regional parliament of Stockholm, responsible for health care
and regional planning in Stockholm. In addition, we founded KaroBio AB, an SME with the
business idea of developing nuclear receptor targeted drugs. The three centres and KaroBio
moved into Novum in 1990.
The creation of KaroBioAB (a nuclear receptor oriented biotech company based in Novum)
almost 20 years ago represented new thinking by bringing a commercial enterprise into an
academic environment. The ideology behind was the insight that the only way to bring advances
at the lab bench to the bed of the patient is via patenting and commercialisation. At the time, this
idea was not uncontroversial but today it is undisputed and, indeed, heavily supported by the
European Union.
Since about seven years we have actively pursued the next phase of making the South Campus
of the Karolinska Institutet into a world renowned research cluster, namely the establishment of
Novum BioCity, a new building side by side with Novum. Novum BioCity aims at further
integration of preclinical and clinical research, medical and technological research, as well as
academic and commercial research. I have recently officially been assigned by President
Harriet Wallberg-Henriksson the task to plan and overlook the scientific activities of Novum
BioCity.
The aim is to create a world renowned research centre with creative and novel contact surfaces
between basic and clinical research, between medical and technological research and between
academic and commercial research.
One important motivation I have had to engage myself in these “institution-building” activities
has been to build up a critical mass of young (and senior) scientists within the field of molecular
and applied endocrinology, with particular emphasis on nuclear receptors. As also stated
elsewhere in this application, I have participated in the supervision of 98 PhD students to the
presentation of their theses as well as supervised 129 postdocs/visiting scientists. Of these 21
have become full professors at different universities around and outside Europe (Rune Toftgård,
Lorenz Poellinger, Jan Carlstedt-Duke, Johan Lund, Örjan Wrange, Magnus IngelmanSundberg, Jim Halpert, Eckardt Treuter, Agneta Mode, Peter Ekman, Håkan Eriksson, Sam
Okret, Åke Pousette, Gunnar Norstedt, Joseph Rafter, Lennart Möller, Anthony Wright, Peter
Zaphiropoulos, Shin—Ichii Hayashi, Martin Göttlicher, and Sari Mäkelä).
I believe that these facts constitute good evidence of our efforts and ability to inspire younger
researchers towards high quality research.
Invited lectures at international meetings:
1.
3rd Int. Congress of Hormonal Steroids, Hamburg, West Germany: "The role of the
intestinal microflora in steroid metabolism". September 1970.
2.
The Royal Society Meeting, London, UK: "Steroids in meconium and faeces from
newborn infants". 1972.
3.
The Journal of Steroid Biochemistry Meeting, Paris, France: "Sexual Differentiation of
Hepatic Steroid Metabolism in the Rat". April 1974.
16
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
4.
III Bile Acid Meeting on Advances in Bile Acid Research, Freiburg i. Br., West Germany:
"Causes of differences between germfree and conventional rats in liver microsomal
metabolism of steroids". September 1974.
5.
Int. Congress of Hormonal Steroids, Mexico: "Neonatal androgenic programming of
hepatic steroid metabolism in rats". September 1974.
6.
Meeting of the Journal of Steroid Biochemistry, Paris, France: "Programming and
differentiation of rat liver enzymes". 1976.
7.
Int. Meeting on Progesterone Receptors in Normal and Neoplastic Tissues, Montreal,
Canada: "Progestin receptor in endometrial carcinoma".1976.
8.
568th Meeting of the Biochemical Society in Aberdeen on Steroid Binding and
Oligomeric Proteins, Aberdeen, Scotland: "Glucocorticoid-receptor interactions in rat
liver". 1976.
9.
III Int. Symposium on Microsomes and Drug Oxidations, Berlin, West Germany: "Studies
on a cytochrome P-450-dependent hydroxylase system active on steroids in Bacillus
megaterium". 1976.
10.
Fogarty Conference on Neonatal Hepatitis and Biliary Atresia, Bethesda, USA: "Steroid
metabolism in the fetal and perinatal period". March 1977.
11.
Int. Symposium on Hormones and Brain Development, Berlin, German Democratic
Republic: "Central control of a cytochrome P-450-dependent steroid hydroxylase in rat
liver". 1978.
12.
Fogarty Conference on Hormones and Cancer, Bethesda, USA: "Estradiol receptor
analysis in human breast cancer tissue by isoelectric focusing in polyacrylamide gel".
March 1978.
13.
Scientific Conf. on Cytochrome P-450: Structural and Functional Aspects, Eberswalde,
German Democratic Republic: "Pituitary control of hepatic steroid metabolism". July
1978.
14.
Nobel Symposium on Central Regulation of the Endocrine System, Stockholm, Sweden:
"Sexual differentiating actions of steroids on the hypothalamo-pituitary-liver axis". 1979.
15.
IV Int. Symposium on Microsomes, Drug Oxidations and Chemical Carcinogenesis, Ann
Arbor, USA: "Characterization of a steroid-hydroxylating cytochrome P-450 of bacterial
origin". 1979.
16.
Workshop of the Society of Urologic Oncology and Endocrinology: Steroid Receptors,
Metabolism and Prostatic Cancer, Amsterdam, The Netherlands: "On the presence of a
major protein, prostatic secretion protein or estramustine-binding protein, in the rat
ventral prostate and in the human prostate". April 1979.
17.
Int. Symposium on the Biochemistry, Biophysics and Regulation of Cytochrome P-450,
Stockholm, Sweden: "The hypothalamo-pituitary-liver axis: a novel regulatory system in
the control of cytochrome P-450". 1980.
18.
Int. Meeting on Endocrines and the Environment, Morristown, USA: "Role of the
hypothalamo-pituitary-liver axis in sex differences in susceptibility of the liver to toxic
agents". 1980.
17
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
19.
Int. Workshop on Nutrition and Cancer, Cambridge, UK: "The effect of intestinal
microflora on the enterophepatic circulation of mercapturic acid pathway metabolites".
July 1980.
20.
Int. Meeting on Steroid Hormone Regulation of the Brain, Stockholm: "Studies on the
glucocorticoid receptor". October 1980.
21.
Int. Meeting on the Prostatic Cell: Structure and Function, Buffalo, USA: "Induction of
cytochrome P-450 and metabolic activation of mutagens in the rat ventral prostate".
1981.
22.
Int. Symposium on Nutrition and the Intestinal Flora, Saltsjöbaden, Sweden: "Metabolism
of steroid hormones in germfree and conventional rats". June 1981.
23.
V Int. Symposium on Microsomes and Drug Oxidations, Tokyo, Japan: "Central control of
sexual differentiation of hepatic steroid metabolism in the rat". July 1981.
24.
II Int. Meeting on Gene Regulation by Steroid Hormones, Detroit, USA: "Functional
analysis of the glucocorticoid receptor by limited proteolysis". September 1981.
25.
Int. Symposium on Corticosteroid Treatment in Allergic Airway Diseases, Copenhagen,
Denmark: "Glucocorticoid-binding proteins in rat liver". October 1981.
26.
Int. Symposium on Medroxyprogesterone Acetate, Geneva, Switzerland: "The
mechanism of hormone action". February 1982.
27.
First American-Swedish Workshop on Individual Susceptibility to Genotoxic Agents in the
Human Population, Research Triangle Park, USA: "On the possible significance of
TCDD receptor based assays in attempts to estimate environmental health hazards".
May 1982.
28.
Serono Symposium No 51 on The Endocrines and the Liver, Rome, Italy: "Studies on the
hypothalamo-pituitary-liver axis: a novel concept in regulation of steroid and drug
metabolism". 1982.
29.
First European Congress on Cell Biology, Paris, France: "Isoelectric focusing and
enzyme-linked immunosorbent assay of steroid hormone receptors". July 1982.
30.
Int. Symposium on Development Pharmacology, Toronto: "Growth hormone: a regulator
of the sexually differentiated steroid metabolism in rat liver". October 1982.
31.
Meeting of the Journal of Steroid Biochemistry, Paris, France: "Regulation of sexually
dimorphic hepatic steroid metabolism by the somatostatin-growth hormone axis". 1982.
32.
Int. Meeting on Extrahepatic Drug Metabolism and Chemical Carcinogenesis, Stockholm,
Sweden: "Soluble receptor proteins in control of gene expression". May, 1983.
33.
Int. Symposium on Hormones and Cancer, Buenos Aires, Argentina: "On the use of
antibodies in studies on glucocorticoid receptor structure". May, 1983.
34.
II Int. Congress on Hormones and Cancer, Monte Carlo, Monaco: "Studies of steroid
hormone receptors in brain". September, 1983.
35.
Nobel Symposium on Steroid Hormone Receptors: Structure and Function, Karlskoga,
Sweden: "On the use of poly- and monoclonal antibodies in studies on the structure and
function of the glucocorticoid receptor". September, 1983.
18
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
36.
Int. Symposium on the Regulation of Androgen Action, Montreal, Canada:
"Characterization of prostatic cytochrome P-450". June, 1984.
37.
IX Int. Congress of Pharmacology, London, UK: "Recent studies on the mechanism of
action of glucocorticoids". August, 1984.
38.
Meeting of the International Union of Physiological Sciences, Jerusalem, Israel: "New
insights into the mechanism of glucocorticoid hormone action". August, 1984.
39.
Int. Symposium on Diet and Prevention of Coronary Heart Disease and Cancer,
Stockholm, Sweden: "Metabolism of xenobiotic compounds". October, 1984.
40.
Argenteuil Symposium: The Role of Receptors in Biology, Brussels, Belgium:
"Purification and DNA binding of mammalian glucocorticoid receptor". October, 1984.
41.
Int. Meeting on P-450 Genes and their Regulation, Airlie, USA: "Growth hormone
regulation of sex-specific hepatic cytochrome P-450 isozymes". April, 1985.
42.
GREMI Symposium: Glucocorticoides aujourd'hui, Paris, France: "Glucocorticoid
receptor-DNA interactions". May, 1985.
43.
IX Nobel Conference on Thioredoxin and Glutaredoxin Systems - Structure and
Function, Lidingö, Sweden: "Regulation, structure and function of the glucocorticoid
receptor". May, 1985.
44.
7th Int. Symposium of the Journal of Steroid Biochemistry on Recent Advances in
Steroid Biochemistry, Seefeld, Austria: "Structure and tissue localization of the
glucocorticoid receptor". June, 1985.
45.
6th Int. Symposium on the Biochemistry of Exercise, Copenhagen: "Characterization and
regulation of growth hormone receptor in rat liver". June, 1985.
46.
3rd ECP Symposium on Diet and Human Carcinogenesis, Aarhus, Denmark: "Naturally
occurring carcinogens protective factors". June, 1985.
47.
IV Int. Conf. on Environmental Mutagens; Satellite Meeting Genetic Toxicology of the
Diet, Copenhagen: "Mutagens formed in the gastro-intestinal tract". June, 1985.
48.
SEPCR Congress on Clinical Applications of Corticosteroids, The Hague, The
Netherlands: "Mechanisms of action of glucocorticosteroids at the subcellular level".
June, 1985.
49.
Gordon Conference on Hormone Action, Kimball Union, New Hampshire, USA:
"Glucocorticoid regulated genes". August, 1985.
50.
5th Int. Conference on Biochemistry, Biophysics and Induction of Cytochrome P-450,
Budapest, August 1985: "Biochemical and biophysical characterization of the TCDD
receptor - a comparison to steroid hormone receptor". August, 1985.
51.
3rd Meadow Brook Conference on the Molecular Mechanism of Steroid Hormone Action,
Rochester, USA: "Mechanism of sex differentiation of rat liver". September, 1985.
52.
Int. Symposium on Monoclonal Antibodies: Basic Principles, Experimental and Clinical
Applications in Endocrinology, Florence, Italy: "Monoclonal antibodies to glucocorticoid
receptors". October, 1985.
19
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
53.
First Int. Congress on Cancer and Hormones: Endocrinology and Malignancy: Basic and
Clinical Issues, Rome, Italy: "Regulation of glucocorticoid receptor". April, 1986.
54.
Second Int. Symposium in Hematology and Oncology organized by The Hematology
Collaborating Group at the Karolinska Hospital under the auspices of the Karolinska
Institute in honour of Prof. J.G. Waldenström: Immunoglobulins and Growth Factors in
Hematology and Oncology, Stockholm: "Glucocorticoid mechanism of action: monoclonal
antibodies as experimental tools". May, 1986.
55.
NATO Advanced Research Workshop on Plant Hormone Receptors, Bonn: "Mechanism
of action of glucocorticoid hormones". August, 1986.
56.
Satellite Symposium of 7th International Congress on Hormonal Steroids: Anti-Steroids,
Marbella, Spain: "Gene expression and hormone receptors". September, 1986.
57.
59th Annual Meeting of the Japanese Biochemical Society, Osaka: "Regulation and
expression of cytochrome P-450 in liver and brain". September, 1986.
58.
The Molecular Biology of Drug Metabolizing Enzymes, London: "Hormonal control of sex
specific cytochrome P-450 isozymes in rat liver". December, 1986.
59.
UCLA Symposia on Molecular and Cellular Biology: Steroid Hormone Action, Park City,
Utah, USA: "Structure, function and localization of the glucocorticoid receptor". January,
1987.
60.
2nd International Workshop on P450 Gene Regulation, Airlie, Virgina, USA: "Cloning and
regulation of cytochrome P45015ß and P45016a in rat liver". April, 1987.
61.
7th International Symposium on Microsomes and Drug Oxidations, Adelaide, Australia:
"Role of endocrine factors in the regulation of cytochrome P-450 expression". August,
1987.
62.
625th meeting of the Biochemistry Society on "Molecular Biology of Hormone Action"
Dublin, Irland: "Mechanism of Action of Glucocorticoid Hormones". September, 1987.
63.
8th European Winter Conference on Brain Research, Tignes/Val d'Isere, France: "On the
Expression and Regulation of the Glucocorticoid Receptor". March, 1988.
64.
"Glucocorticoids - from cloning to clinic", Edinburgh, England. May, 1988.
65.
8th International congress of Endocrinology, Kyoto, Japan: "The dioxin and
glucocorticoid receptors: two similar gene regulatory proteins". July, 1988.
66.
6th Biophysics-Biochemistry of cytochrome P-450 congress, Vienna, Austria:
"Glucocorticoid & dioxin receptors - a comparison". July, 1988.
67.
Fourth International Symposium on Cellular Endocrinology, Lake Placid, USA:
"Structure, function and regulation of the glucocorticoid receptor". August, 1988.
68.
NATO Advanced Research Workshop on "Molecular Mechanisms and Consequences of
Activation of Hormone and Growth Factor Receptors, Nafplion, Greece: "Glucocorticoid
receptor". September, 1988.
69.
Molecular biology in drug design and in drug production, Uppsala, Sweden: "Role of
ligand binding in glucocorticoid receptor function". December, 1988.
20
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
70.
9th International symposium of the Journal of Steroid Biochemistry, Las Palmas, Canary
Islands, Spain: "Expression and structure of the Glucocorticoid Receptor". May, 1989.
71.
Biochemical Society meeting, Host Colloquium on "Development of Mixed-Function
Oxidases", Surrey, UK: "The cytochromes P-450 of brain and their role in the metabolism
of neurosteroids". July, 1989.
72.
Molecular Biology and Pathophysiology of Hormone Regulation and Actions, Heidelberg,
West Germany: "Expression, structure and regulation of the glucocorticoid receptor".
July, 1989.
73.
FASEB Summer Research Conference: "Nutrients, Gene Expression, and Cancer",
Copper Mountain, Colorado, USA: "Mechanisms of GH effects on liver cytochrome P450 isozymes". July, 1989.
74.
NATO Advanced Study Institute on "Molecular aspects of monooxygenases and
bioactivation of toxic compounds", Cesme, Izmir, Turkey: "Hormonal Regulation of P-450
Gene Expression" and "Xenobiotic Regulation of P-450 Gene Expression". September,
1989.
75.
Fourth International Symposium in Hematology and Oncology, Stockholm, Sweden:
"Nutrition and cancer". September, 1989.
76.
Steroid Receptors, Transcription Factors, and Gene Expression, San Diego, USA:
"Mechanisms of steroid nonresponsiveness in mutant cell lines". February, 1990.
77.
NORDTOX-90, 1st Nordic Conference of Toxicology and 8th Annual Meeting of Nordic
Environmental Mutagen Society, Beito, Norway: "Mechanism of dioxin regulation of
cytochrome P-450". March, 1990.
78.
Berzelius symposium, The Swedish Society of Medicine, Stockholm, Sweden: "Ligandsteroid receptor interactions". March, 1990.
79.
Scandinavian Physiological Society Meeting, Lund, Sweden: "On the use of molecular
biology in endocrinology". May, 1990.
80.
VIIIth International Symposium Microsomes and Drug Oxidations, Karolinska Institutet,
Stockholm, Sweden: "Receptor-mediated regulation of gene expression". June, 1990.
81.
Eighth international conference on Methods in protein sequence analysis, Kiruna,
Sweden: "Steroid receptor-DNA interactions". July, 1990.
82.
NATO ASI on Biological Signal Transduction, Spetsai, Greece: "Steroid Receptors I:
General background, steroid structure and metabolism, purification and cloning of steroid
receptors, members of the steroid receptor supergene family". "Steroid receptors II:
Regulation of expression of the glucocorticoid receptor (GR) gene. Bacterial expression
of the DNA binding domain DBDr) of GR. The three-dimensional structure of the DBDrDNA complex". August, 1990.
83.
First Düsseldorf Symposium on Immunotoxicology: Molecular Mechanisms of Dioxin
Action on Cell Growth and Differentation, Düsseldorf, Germany: "TCDD receptor:
physicochemical characteristics and its significance for toxicological effects". October,
1990.
84.
Hepatic Metabolism and Disposition of Endo- and Xenobiotics, Freiburg, Germany:
"Comparative Studies of the Glucocorticoid and TCDD-Receptors". October, 1990.
21
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
85.
Biological Basis For Risk Assessment of Dioxins & Related Compounds, Banbury, USA:
"Molecular biology and physiology of TCDD receptor - DNA interactions". October, 1990.
86.
Symposium in honour of Professor Minor J. Coon, Ann Arbor, USA: "The glucocorticoid
receptor: Structure, function and regulation". November, 1990.
87.
Xenobiotics and Cancer: Implications for chemical carcinogenesis and cancer
chemotherapy, Tokyo, Japan: "The molecular biology of the glucocorticoid and dioxin
receptors". November, 1990.
88.
First International symposium on hormonal carcinogenesis, Cancun, Mexico: "Sexual
dimorphism of hepatic steroid hormone metabolism and its significance for chemical
hepatocarcinogenesis". March, 1991.
89.
Cytochrome P450: Advances and prospects, Atlanta, USA: "Regulation of rodent
cytochrome P-450 gene expression by steroid hormones". April, 1991.
90.
10th International Symposium of the Journal of Steroid Biochemistry and Molecular
Biology, Paris, France: "Glucocorticoid receptor: structural and functional studies". May,
1991.
91.
7th International Conference "Biochemistry & Biophysics of Cytochrome P-450; Structure
& Function, Biotechnological & Ecological Aspects", Moscow, U.S.S.R: "Molecular
mechanisms in regulation of cytochrome P-450 gene expression". August, 1991.
92.
Gordon Conference on Hormone Action, New Hampshire, USA: "Structure and Function
of the Three Domains of the Glucocorticoid Receptor". August, 1991.
93.
Arolla Workshop 1991 "From Receptor to Gene", Arolla, Switzerland: "Structure and
Function of the Three Domains of the Glucocorticoid Receptor". August, 1991.
94.
International Symposium on A Molecular View of Steroid Biosynthesis and Metabolism,
Jerusalem, Israel: "Hepatic steroid metabolism is controlled by the sexually dimorphic
pattern of growth hormone secretion in both normal and dwarf rats". October, 1991.
95.
European Research Conference on "Mechanism in Toxicity", Klingenthal, Alsace,
France: "TCDD receptor(s) and their relevance for carcinogenesis". November, 1991.
96.
Keystone Symposia on Molecular and Cellular Biology, Steroid/thyroid receptor gene
super family, Tamarron, Colorado, USA: "Structural and functional studies on the
glucocorticoid receptor". February, 1992.
97.
Centre de Recherche du Chul, Québec, Canada: "On the structure and function of the
glucocorticoid receptor". May, 1992.
98.
Wallenberg Symposium, The Metabolic syndrome, Gothenburg, Sweden: "Mechanism of
action of steroid hormones". May, 1992.
99.
NOMBA, Progress in Molecular Biology, Helsinki, Finland: "Molecular biology of the
glucocorticoid receptor". May, 1992.
100.
Endocrine Society Meeting, San Antonio, Texas, USA: "Overexpression in Bacteria,
Yeast and Eukaryotic Cells of Steroid Receptors and Steroid Receptor Domains". June,
1992.
101.
9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, Israel:
"Mechanisms of regulation of expression of hepatic cytochrome P-450". July, 1992.
22
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
102.
5th International congress on Cell Biology, Madrid, Spain: "Functional analysis of the
three domains of the glucocorticoid receptor". July, 1992.
103.
NATO/FEBS on New Developments in Lipid-Protein Interactions and Receptor Function,
Spetsai, Greece: "Determinants for DNA binding site recognition by the glucocorticoid
receptor". "Fatty acids activate a chimera of the clofibric acid-activated receptor and the
glucocorticoid receptor". August, 1992.
104.
11th International Conference on Comparative Physiology, The Differences between the
sexes, Crans-sur-Sierre, Switzerland: "Why are there male and female livers and
kidneys?". September, 1992.
105.
The University of Oslo, Jahreföreläsning, Oslo, Norge: "The functional architecture of the
glucocorticoid receptor". September, 1992.
106.
Keith Harris lecture, Australian Endocrine Society, Adelaide, Australia: "The molecular
biology of the glucocorticoid receptor". October, 1992.
107.
Invited lecturer at Collége de France, Paris, France: "Functional architecture of the
glucocorticoid receptor". October, 1992.
108.
Invited lecturer at University of California, Berkeley, USA: "Functional architecture of the
glucocorticoid receptor". October, 1992.
109.
The Karolinska-Minnesota Frontiers of Medicine Symposium, Minnesota, USA:
"Functional architecture of the glucocorticoid receptor". October, 1992.
110.
American association for the study of liver diseases, Chicago, Illinois, USA: "Hormonal
regulation of Cytochromes P-450". November, 1992.
111.
The 23rd International Symposium of the Princess Takamatsu Cancer Research Fund,
Tokyo, Japan: "Induction of cytochrome P450 1A isozymes by heterocyclic amines and
other food derived compounds". November, 1992.
112.
Functions and structures of genes and proteins, Mariehamn, Åland: "Structure and
function of the glucocorticoid receptor". November, 1992.
113.
Perspectives in Nutrition Research Towards Year 2000, Oslo, Norway: "Molecular
Nutrition: Regulation of Gene Expression by Fatty Acids". December, 1992.
114.
Receptor Mediated Biological Processes: Implication for Evaluating Carcinogens, Austin,
Texas. December, 1992.
115.
Symposium on Fat and Gene Expression, New Orleans, U.S.A.: "Fatty acid activation of
the peroxisome proliferator activated receptor (PPAR), a member of the nuclear receptor
supergene family".March, 1993.
116.
Biochemistry, Endocrinology and Pharmacology of Nuclear Receptors, Marburg,
Germany: "Fatty acid activation of PPAR". May, 1993.
117.
11th International Symposium of The Journal of Steroid Biochemistry and Molecular
Biology "Recent advances in steroid biochemistry and molecular biology", Seefeld,
Austria: "Structure and function of the glucocorticoid receptor". May/June, 1993.
118
The Karolinska Institute and the Summer University of Southern Stockholm,
"Understanding Signal Transduction", Stockholm, Sweden: "Steroid/thyroid hormone
receptors". June, 1993.
23
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
119.
18th International Congress of Chemotherapy, "Principles of endocrine treatment of
cancer - basic aspects and clinical regimens", Stockholm, Sweden: "Basic aspects on
steroid hormone actions". June, 1993.
120.
International Symposium on Antioxidants and Disease Prevention, Biochemical,
Nutritional, and Pharmacological Aspects, Stockholm, Sweden: "Control of Gene
Expression by Fatty Acids and Retinoids". June/July, 1993.
121.
22nd Meeting of the Federation of European Biochemical Societies, Stockholm, Sweden:
"The functional architecture of the glucocorticoid receptor". July, 1993.
122.
Second Asia-Pacific Symposium on Environmental and Occupational Health – Toxicological Studies, Kobe, Japan: "Mechanisms of Induction of Cytochrome P450 by
Environmental Agentsparticipation of Ligand Activated Transcription Factors from Two
Different Gene Families". July, 1993.
123.
5th International CBT Symposium, "Intracellular hormone receptors and liganddependent transcriptional regulation", Stockholm, Sweden: "Activation of PPAR by fatty
acids". September, 1993.
124.
Instituto Juan March de Estudios e investigaciones, Centre for International Meetings on
Biology. Workshop on Neuroendocrinology of Growth. Madrid, Spain: "Mechanisms of
sex differentiation and growth hormone regulation of hepatic P450 genes in the rat".
October, 1993.
125.
8th International Conference on Cytochrome P450, Lisbon, Portugal: "Mechansims of
sex differentiation and growth hormone regulation of hepatic P450 genes in the rat".
October, 1993.
126.
4th International Thyroid Symposium on "Genetic defects of thyroid and steroid hormons
receptors: molecular basis and clinical expression", Ulm, Germany: "Thyroid and steroid
hormone receptor family". November, 1993.
127.
Biochemical Society Meeting 649, London, U.K.: "Receptor-mediated regulation of drug
metabolising enzymes". December, 1993.
128.
Norsk Biokjemisk Selskaps 30 årsjubileumsmöte: "Novel aspects on ligand activated
transcription factors". January, 1994.
129.
Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico: "The dioxin
receptor - another ligand activated transcription factor". February, 1994.
130.
Symposium on Eukaryotic Gene Expression and Regulating Signals, New York:
"Functional architecture of the glucocorticoid receptor and characteristics of some novel
members of the steroid/thyroid hormone receptor super family". April, 1994.
131.
The Lundberg Symposium, Gothenburg: "Nuclear receptors - an expanding super gene
family". May, 1994.
132.
Nordic Meeting on Biochemical and Medical Aspects of Lipid Metabolism in Peroxisomes
and Mitochondria, Huddinge, Sweden: "Activation of the PPAR". May, 1994.
133.
The First International Conference on Steroids and Bone, Florence, Italy: "The functional
architecture of the glucocorticoid receptor". May, 1994.
24
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
134.
United European Gastroenterology week, Oslo, Norway: "Fatty acid control of gene
expression via a member of the nuclear receptor supergene family (PPAR)". June, 1994.
135.
XIIth International Congress of Pharmacology, Montréal, Québec, Canada: "Fatty acid
activation of PPAR". July, 1994.
136.
10th International Symposium on Microsomes & Drug Oxidations, Toronto, Canada:
"Functional analysis of flanking sequences of sex-specific P-450 genes expressed in rat
liver". July, 1994.
137.
Second International Symposium on Hormonal Carcinogenesis, Novum, Stockholm:
"Novel Aspects on Ligand Activated Transcription Factors in Control of Cytochrome P450". July, 1994.
138.
NATO Advanced Study Institute on Molecular Mechansims of Transcellular Signaling:
"From the Membrane to the Gene", Spetsai, Greece: "Recent developments in the field
of the nuclear receptor supergene family" and "The dioxin receptor - another ligand
activated transcription factor". August, 1994.
139.
University of Wisconsin-Madison: "Steroid Receptor Superfamily Symposium", Madison,
USA: "Functional analysis of the glucocorticoid receptor". September, 1994.
140.
IX International Congress on Hormonal Steroids. Dallas, Texas, USA: "Activation of the
PPAR". September, 1994.
141.
Health Research in Quebec and the world: today and tomorrow: Montréal, Canada:
"University-Industry Partnership in Sweden". October, 1994.
142.
Worcester Foundation for Experimental Biology, Gregory Pincus Lecture, Shrewsbury,
MA, USA: ”Functional organization of the glucocorticoid receptor”. November, 1994.
143.
Symposium on "Bridging Basic Science and Liver Disease". Boston, USA: "Mechanisms
of growth hormone regulation of sexually differentiated gene expression in the liver".
November, 1994.
144.
Receptor Mediated Mechanisms in Carcinogenesis, Lyon, France: "Nuclear Receptors
and Chemical Carcinogenesis". November, 1994.
145.
Keystone Symposia conference on ”Molecular Toxicology”, Keystone, USA: ”Functional
architecture of the dioxin receptor/arnt heterodimer”. January, 1995.
146.
An AACR Special Conference in Cancer Research: ”Mechanism of action of retinoids,
vitamin D, and steroid hormones”, Whistler, British Columbia, Canada: ”Mechanisms of
activation and action of PPAR (Peroxisome Proliferator Activated Receptor). January,
1995.
147.
Sterling lecture, University of Pennsylvania, Philadelphia, USA: Mechanism of action of
the glucocorticoid receptor and of the peroxisome proliferatoractivated receptor (PPAR).
March, 1995.
148.
EMBO Workshop; Structure and Function of Steroid and Nuclear Receptors, Alghero,
Sardinia, Italy: ”Transcriptional activation by the glucocorticoid receptor: Role of the 1
domain”. April, 1995.
149.
Pharmacology & Toxicology 50th Anniversary Symposium, Perspectives in the
development and safety of new medicines: Biological diversity and structure specificity,
25
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
Copenhagen, Denmark: ”Mechanisms of Regulation of Drug Metabolizing Enzymes”.
May, 1995.
150.
12th International Symposium of the Journal of Steroid Biochemistry and Molecular
Biology. ”Recent Advances in Steroid Biochemistry and Molecular Biology”, Berlin,
Germany: ”Functional Analysis of the glucocorticoid receptor”. May, 1995.
151.
The Aspen Institute: Peroxisomes: Biology and Role in Toxicology and Disease, Aspen,
USA: ”Fatty acid signalling of peroxisome proliferator-activated receptor”. June/July,
1995.
152.
VII International Congress of Toxicology, Seattle, USA: ”Receptor-mediated toxicity”.
July, 1995.
153.
Gordon Research Conference on Hormone Action, New Hampshire, USA: ”Functional
organization of the dioxin receptor-Arnt complex”. July/August, 1995.
154.
The Rank Prize Funds, Mini-Symposium on Nutrients as Regulators (Nutrient Sensing),
Grasmere, England: “Regulation of gene expression by fatty acids”. September, 1995.
155.
7th International CBT Symposium: Nuclear Orphan Receptors: Novel Regulators in
Physiology and Pathology, NOVUM, Sweden: ”Mechanism of signal transduction of
PPAR”. September, 1995.
156.
International Symposium on ”DHEA Transformation into Androgens and Estrogens in
Target Tissues: Intracrinology”, Québec, Canada: ”Activation of peroxisome proliferator
activated receptor (PPAR)”. September, 1995.
157.
The European Respiratory Society Annual Congress, Barcelona, Spain: ”Glucocorticoid
receptor and transcription factor interactions”. September, 1995.
158.
International Symposium on Control Mechanisms of Carcinogenesis, Mainz, Germany:
”Ligand activated transcription factors”. September, 1995.
159.
The British Biochemical Society Meeting No. 657, Aberdeen, U.K.: ”Control of gene
expression by fatty acids: Role of the peroxisome proliferator activated receptor (PPAR)”.
December, 1995.
160.
From Invention to Business in Biotechnology, Helsinki, Finland: ”Future scenarios for
Biocenters”. January, 1996.
161.
Keystone Symposia on Molecular and Cellular Biology, Steroid/Thyroid/Retinoic Acid
Gene Family, Lake Tahoe, California: “Cloning of a novel estrogen receptor (ER)”.
March, 1996.
162.
2nd Oulu Symposium on Molecular Approaches to Reproductive Health, Oulu, Finland:
“Orphan receptors and the search for endogenous ligands”. May, 1996.
163.
International Society for Endocrinology, San Francisco, USA: ”Negative cross-talk
between the glucocorticoid receptor and other signal transduction pathways”. June,
1996.
164.
NATO/FEBS Advanced Study Institute, International Summer School on Molecular
Mechanisms of Signaling and Targeting, Spetsai, Greece: ”Orphan nuclear receptors an exciting development of the steroid/thyroid hormone receptor field” and ”Growth
hormone as determinant of hepatic sexual dimorphism”. August, 1996.
26
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
165.
Estrogen and the Blood Vessel Wall Symposium, Seattle, Washington, USA: ”Cloning,
Expression and Function of a Novel Estrogen Receptor”. September, 1996.
166.
KBF-Symposium Molecuar Targets for Drug Development, Braunschweig, Germany:
”Steroid receptors as molecular targets for drug development”. September, 1996.
167.
SPBBM, Colloque GERMÉ, PPARs, nutriments and xenobiotics: as mediators of cell
regulation? Dijon, France: “Regulation of PPAR by glucocorticoids and nor-epinephrine”.
September, 1996.
168.
Tore Nilson symposium on ”Aspects of hormonal regulation of artherosclerosis”,
Stockholm: ”Fatty acids and gene regulation”. September, 1996.
169.
Steroid Receptor Superfamily Symposium, Madison, USA: ”Characteristics and function
of the novel estrogen receptor ”. September, 1996.
170.
Deutsche Forschungsgemeinschaft, Symposium Hormonally Active Agents in Food,
Kaiserslautern, Germany: ”Novel aspects of environmentally and dietary related ligand
activated transcription factors”. October, 1996.
171.
University of Leicester, MRC Toxicology Unit, Leicester, U.K.: ”What new can we learn
about estrogens in light of the discovery of the novel estrogen receptor ”. February,
1997.
172.
Workshop on ”Universities in the Cross-Streams of Globalisation and Information
Technology”, Italy: ”Government - Industry - University interaction”. February, 1997.
173.
31st International Meeting of the European Society for Clinical Investigation (ESCI), Kiel,
Germany: “Functional characteristics of estrogen receptor ”. March, 1997.
174.
NIH, Bethesda, USA: “Recent insights into mechanisms of glucocorticoid action - new
crosstalk and coactivators”. April, 1997.
175.
Mechanisms of action of estrogens and physiological needs, Chantilly, France: “ and 
estradiol receptors”. April, 1997.
176.
Frontiers in Estrogen Action, Key West, USA: “Identification and characterization of
ER”. May, 1997.
177.
The paradoxes of growth hormone action, Fiskebäckskil, Sweden: “Free fatty acids mediators of GH action”. May, 1997.
178.
The Endocrine Society 79th Annual Meeting, ENDO ‘97, Minneapolis, USA: ER: a new
isoform of the estrogen receptor”. June, 1997.
179.
Marabou symposium: Diet and genetic interactions, Stockholm, Sweden: “Fatty acids
and gene expression”. June, 1997.
180.
Paediatric Endocrinology 1997, Joint Meeting of ESPE and LWPES, in collabora-tion
with APEG, JSPE and SLEP, Stockholm, Sweden: “Cloning and function of the novel
estrogen receptor ”. June, 1997.
181.
Eurotox Congress in collaboration with the Danish Society of Pharmacology and
Toxicology, Aarhus, Denmark: “Receptor mediated toxic responses”. June, 1997.
27
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
182.
FEBS Special Meeting, Cell Signalling Mechanisms; from membrane to nucleus,
Amsterdam, The Netherlands: “Novel insights into estrogen mechanism of action”.
June/July, 1997.
183.
XXXIII International Congress of Physiological Sciences IUPS 1997, St. Petersburg,
Russia: “Estrogen receptor  - tissue distribution and functional properties”. July, 1997.
184.
NIEHS Conference on Estrogens in the Environment IV: Linking Fundamental
Knowledge, Risk Assessment, and Public Policy, Arlington, Virgina, USA: “Hormone
action of a new estrogen receptor: ER-“. July, 1997.
185.
Gordon Research Conference on Hormone Action, New Hampshire, USA:
“Characterization of a novel estrogen receptor”. July/August, 1997.
186.
Gordon Research Conference on Hormonal Carcinogenesis, Tilton, USA: ”Novel insights
into the mechanism of action of estrogens in the light of the discovery of a second
estrogen receptor gene”. July/August, 1997.
187.
17th International Congress of Biochemistry and Molecular Biology, San Francisco, USA:
“Ligand activated transcription factors in control of cytochrome P450”. August, 1997.
188.
The fifth CFN Symposium, Effects of Toxicants on Gene Expression and Intracellular
Signalling, Saltsjöbaden, Sweden: “Impact of environmental pollutants on nuclear
receptors”. September, 1997.
189.
Symposium on Phytoestrogen Research Methods, Chemistry, Analysis, and Biological
Properties, Tucson, Arizona, USA: ”The estrogen -receptor and its interaction with
phytoestrogens”.
190.
Workshop on Estrogen Action, New Jersey, USA: ”Expression and Function of ER”.
October, 1997.
191.
XV Congrès de la Société Francaise d’Endocrinologie, Paris, France: ”Cloning,
expression and role of a novel estrogen receptor”. October, 1997.
192.
9th International CBT Symposium, Steroid and Orphan Nuclear Receptors, Stockholm,
Sweden: ”OR1 and PPAR - two major regulators of lipid metabolism”. October, 1997.
193.
Molecular basis of sex hormone receptor function - New targets for intervention, Berlin,
Germany: ”Estrogen receptor ”. October, 1997.
194.
EMRC Workshop ”Crosstalk between steroid receptors and other transcription factors:
molecular basis for immunomodulatory and anti-inflammatory effects of steroids”, Ottrott,
Alsace, France: ”PPAR and OR-1: Two major regulators of lipid metabolism”. November,
1997.
195.
Academy of Military Medical Sciences, Beijing, China: “Orphan receptors - a rapidly
developing field with nutritional implications”. November, 1997.
196.
Receptor Biology Roundtable, Center for Executive Education at Babson College,
Massachusetts, USA: ”Estrogen receptor isoforms”. December, 1997.
197.
Seminar at CIIT, North Carolina, USA: ”Nuclear receptors as mediators of chemicalinduced toxic responses: Mechanism of peroxisome proliferator-activated receptor”.
December, 1997.
28
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
198.
Distinguished lecturer seminar, NIEHS, Research Triangle Park, North Carolina, USA:
”The Estrogen Receptor Beta”. December, 1997.
199.
AAAS Annual Meeting and Science Innovation Exposition, Philadephila, Pennsylvania:
Cochair at the symposium ”Manipulation of Science by Vested Interests: Money and
Power versus Public Health”. February, 1998.
200.
University of Colorado Health Sciences Center, Department of Pathology, Denver, USA:
“Novel developments in nuclear receptors: postreceptor signalling and estrogen receptor
”. February, 1998.
201.
Keystone Symposia on Breast and Prostate Cancer, Copper Mountain, Colorado, USA:
“Mechanism of Action of Estrogen Receptor ”. February, 1998.
202.
Tokyo Medical Association Meeting (Tokyo Society of Medical Science), Tokyo, Japan:
“New developments in nuclear receptors: crosstalk, coactivators and orphan receptors”.
February, 1998.
203.
Symposium for Sex Difference and Similarity Society, Tokyo, Japan: “New developments
in nuclear receptors: crosstalk, coactivators and orphan receptors”. February, 1998.
204.
International Symposium on Biology of Prostate Growth, Bethesda, Maryland, USA:
“Estrogen  receptor in prostate”. March, 1998.
205.
Estrogens as initiators and promoters in breast and prostate cancer, Chantilly, Virginia,
USA: “Structure and properties of estrogen receptor ”. March, 1998.
206.
Keystone Symposia on Molecular & Cellular Biology, Nuclear Receptor Gene Family
Conference, Lake Tahoe, Nevada: ”Estrogen receptor  predicted effects of estrogen”.
March/April, 1998.
207.
2nd Congress of Molecular Medicine, Berlin, Germany: ”Biology of the novel estrogen
receptor ER”. May, 1998.
208.
IV European Congress of Endocrinology, Sevilla, Spain: ”Steroid receptors - New
dimensions”. May, 1998.
209.
18th Blankenese Conference, Orphan receptors and novel ligands, HamburgBlankenese, Germany: ”OR-1 and peroxisome proliferator-activated receptors (PPAR) two major regulators of lipid metabolism”. May, 1998.
210.
Frontiers in Estrogen Action, Rio Grande, Puerto Rico: ”Signalling via estrogen receptor
”. May, 1998.
211.
NFOG ’98, The Federation of Scandinavian Societies of Obstetrics and Gynecology,
Århus, Denmark: ”Estrogen receptor : A new dimension in estrogen receptor research”.
May, 1998.
212.
Nordtox/NordEMS-98, The 5th Nordic Toxicology Meeting, Helsinki, Finland: “In vitro
studies for understanding toxic mechanisms in vivo”. May, 1998.
213.
European Federation of Endocrine Societies, 2nd Postgraduate Course in Molecular and
Cellular Endocrinology, Turku, Finland: “The steroid/thyroid hormone receptor family”.
June, 1998.
29
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
214.
Laboratory Medicine 98, Turku, Finland: “Estrogen Receptor ”. Keynote lecture. June,
1998.
215.
3rd International Symposium on Women’s Health and Menopause, Risk Reduction
Strategies - Improved Quality of Health, Florence, Italy: “Novel mechanisms of estrogen
action” and ”Estrogen receptor  - a new hope for tissue specific HRT”. June, 1998.
216.
Xth Int. Congress on Hormonal Steroids, Québec, Canada: ”Estrogen receptor  - a new
dimension in estrogen mechanism of action”. Keynote lecture. June, 1998.
217.
Int. Congress of Toxicology, Paris, France: “PPAR activation and its consequences in
experimental animals”. July, 1998.
218.
Gordon Research Conference, New Hampshire, USA: “Expression and function of the
new estrogen receptor: ER”. July, 1998.
219.
Int. Congress of Pharmacology, München, Germany: ”Peroxisome proliferator activated
receptor or PPAR”. July, 1998.
220.
The Society for the Study of Reproduction, Texas, USA: “Physiology and molecular
biology of estrogen receptor “. Keynote lecture. August, 1998.
221.
NATO/FEBS Advanced Study Institute, International Summer School on Molecular
Mechanisms of Transcellular Signalling: From Membrane Receptors to Trancription
Factors, Spetsai, Greece: ”Coactivators and corepressors in nuclear receptor function”
and ”Novel insights into the role of orphan nuclear receptors”. August, 1998.
222.
European Teratology Society, Stockholm: “Basic concepts of hormone-receptor
interactions”. September, 1998.
223.
3rd Int. Symp on Hormonal Carcinogenesis, Seattle, Washington, USA: “Estrogen
receptor  - an important player in estrogen action”. September, 1998.
224.
Estrogens and Human Health, Urbana, Illinois, USA: ”Estrogen receptors  and ”.
October, 1998.
225.
Sex-Hormones, Their Receptors and Biological Response, Louisville, Kentucky, USA:
“New dimensions in estrogen action: ER”. October, 1998.
226.
Steroid hormone action at the turn of the century. Four decades after puff induction by
ecdysone, Marburg, Germany: ”Recent paradigm shifts in our understanding of estrogen
signalling”. October, 1998.
227.
Sex-Steroids and the Somatotropic Axis, La Playa, Naples, Florida, USA: ”Intracellular
transacting signals”. October, 1998.
228.
Breast and menopause, Wroclaw, Poland: “Estrogen receptor ”. October, 1998.
229.
Nuclear Receptors - Minisymposium, Oslo, Norway: “Introduction into the nuclear
receptor field”. November, 1998.
230.
Sixth Annual Meeting of Japan Hormonal Steroid Society, Osaka, Japan: Keynote
Lecture “Estrogen receptor  - a new dimension in estrogen mechanism of action”.
November, 1998.
30
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
231.
The first Märta Philipson Symposium in Pediatric Research, Stockholm ”Estrogen
receptor : Functional role for a new estrogen receptor in mammalian development”.
December, 1998.
232.
AACR Special Conference on The Steroid Receptor Superfamily, Indian Wells, CA, USA:
”Estrogen receptor  - new exciting developments”. January, 1999.
233.
23rd International LOF-symposium on phyto-oestrogens, Gent, Belgium: ”The estrogen
receptor  and its interaction with phytoestrogens”. January, 1999.
234.
ILSI Health and Environmental Science Institute, Nassau, Bahamas: ”Nuclear
Receptors”. January, 1999.
235.
Endocrine Disruptors, Keystone, Lake Tahoe, USA, February, 1999: ”Properties,
distribution & function of ER”. February, 1999.
236.
Women’s Health Roundtable, Pasadena, USA: Estrogen receptors and other nuclear
receptors”. February, 1999.
237.
Estrogen and progesterone receptors and their ligands, Society for Gynecologic
Investigation, Atlanta, USA: ”Estrogen Receptors: Alpha and Beta”. March, 1999.
238.
The 4th Congress of the European Society for Gynecologic and Obstetric Investigation,
Madonna di Campiglio, Italy: ”New dimensions in estrogen mechanism of action offer
new hopes for therapy of diseases in the postmenopausal woman”. March, 1999.
239.
Frontiers in Estrogen Action, Dana Point, California, USA: ”The nuclear receptors”. April,
1999.
240.
18th Joint Meeting of the British Endocrine Societies, Insulin resistance and
cardiovascular disease: mechanisms and consequences, Bournemouth, UK: “Nuclear
receptors involved in lipid metabolism: PPAR, ER, OR-1 and RLD-1”. April, 1999.
241.
German Society of Endocrinology and German Society of Human Genetics, International
Symposium on Breast and Prostate Cancer: Genes, Hormones and the Environment,
Casle Elmau, close to Garmisch-Partenkirschen, Germany: ”Recent advances in our
understanding of nuclear receptor action”. April, 1999.
242.
Keystone Symposium on The PPARs: Transcriptional links to obesity, diabetes and
cardiovascular disease, Keystone Resort, Colorado: ”Downstream Modulators of PPAR
Action”. April/May, 1999.
243.
Endothelial derived vasoactive substances and free radicals in perinatal biology, NIH,
Washington: “Estrogen receptors - current concepts”. May, 1999.
244.
Directors Seminar, NIH, Washington: ”New dimensions in nuclear receptor signaling”.
May, 1999.
245.
EMBO Workshop, Steroid and Nuclear receptors, Villefranche, France: “Biology and
mechanism of action of estrogen receptor ”. May, 1999.
246.
Int. Conference on Diet and Prevention of Cancer, Tampere, Finland: “ER - an
antioxidant receptor”. May/June, 1999.
247.
Gordon Conference on Mammary Gland Biology, Hennecker, New Hampshire, USA,
June 1999: ”ER: New excitement”. June, 1999.
31
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
248.
XIIIth International Symposium on Gnotobiology, Djurönäset, Stockholm: Steroid
hormones, nutrients, nuclear receptors and coactivators – important players in control of
gene expression”. June, 1999.
249.
Nobelsymposium 113, “Estrogens and women’s health – benefit or threat?”, Karlskoga,
Sweden: “ER - a new paradigm in estrogen mechanism of action”. June/July, 1999.
250.
Gordon Conference Research on Hormonal Carcinogenesis, New Hampshire, USA:
“Estrogen receptor : structure and function”. August, 1999.
251.
11th International Conference on Cytochrome P450, Sendai, Japan: “Nuclear receptors –
and update”. August, 1999.
252.
Japanese Endocrine Disruptor Research Project, Tokyo, Japan: “ER - a new dimension
in understanding of estrogen action”. September, 1999.
253.
6th International Congress on Hormones and Cancer, Jerusalem, Israel: “Recent
advances in our understanding of the respective biological roles of estrogen receptor 
and estrogen receptor ”. September, 1999.
254.
Neuronal and cognitive effects of oestrogens, London, England: “New horizons in
estrogen mechanisms of action – estrogen receptor ”. September, 1999.
255.
ECCO10 – the European Cancer Conference, Vienna, Austria: “Estrogen receptor beta –
new developments”. September, 1999.
256.
International workshop: Estrogens and Male Reproduction (EMR), Isola Capo Rizzuto,
Crotone, Italy: “The role or estrogen receptor beta in male reproductive tissues”.
September, 1999.
257.
The 9th International Menopause Society World Congress on the Menopause,
Yokohama, Japan: “ER - new dimensions in estrogen mechanism of action”. October,
1999.
258.
Svenska Mässan, “From Idea to Blockbuster”, Gothenburg: “Novel nuclear receptors – a
paradigm shift in drug development”. November, 1999.
259.
SERMs: Implications for Prevention and Treatment of Breast Cancer, Philadelphia, USA:
“ER: More Surprises”. November, 1999.
260.
National Institutes of Health, Menopause and Women’s Health – a Global Approach,
USA: “Physiological role of estrogen and estrogen receptors". November, 1999.
261.
2nd Biennial International Meeting Flemish Gyneacological Oncology Group, Brussels,
Belgium: “New insights in ER research – The ER “. December, 1999.
262.
International Symposium on Induction of Drug Metabolism From Molecular Mechanisms
to Drug Approval, Stockholm, Sweden: “Recent advances in our understanding of
receptor mediated induction of drug-metabolizing enzymes”. December, 1999.
263.
The Second International Symposium on: The Molecular Biology of Breast Cancer,
Lillehammer, Norway: “Estrogen receptors  and  in the rodent mammary gland”.
March, 2000.
264.
Congres Infertiliteit, gynaecologie en obstetrie anno 2000, Rotterdam, Netherlands:
“Estrogen receptors; modulation and clinical practise". March, 2000.
32
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
265.
Estrogens: From research to clinical practice (Hormone-dependent cancers and
menopause), Montpellier, France: “ER - a paradigm shift in our understanding estrogen
action”. March, 2000.
266.
Keystone Symposia, Nuclear Receptors 2000, Steamboat Springs, Colorado, USA: “ER
- Surprises never end”. March, 2000.
267.
Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer
Therapy, Stockholm, Sweden: “Roles of estrogen receptor  in the CNS”. April, 2000.
268.
Nuclear Receptors in the Brain, Potential targets for therapeutic agents, Oegstgeest, The
Netherlands: Keynote lecture: “News and views on nuclear receptors”. April, 2000.
269.
4th Annual Frontiers in Estrogen Action, Palm Beach, Florida, USA: Coorganizer and
cochairman. April, 2000.
270.
27th European Symposium on Calcified Tissues, Tampere, Finland: Keynotelecture:
“Biological role of ER and ER“. May, 2000.
271.
Estrogens: bone and vascular targets, Paris, France: “Estrogen receptor  - a paradigm
shift in understanding estrogen action”. May, 2000.
272.
SFT seminar on Phytoestrogens, Stockholm, Sweden: “A paradigm shift in our
understanding of estrogen action”. May, 2000.
273.
Swiss Bone and Mineral Society, Basel, Switzerland: “ER - a new dimension in
estrogen action”. May, 2000.
274.
Int. Conf. on the Female Reproductive Tract, Frauenwörth, Germany: “Estrogen receptor
 - role in reproduction”. May, 2000.
275.
Annual Meeting of the German Endocrine Society, München, Germany: “New
dimensions in estrogen receptors’ mechanisms of action”. June, 2000.
276.
6th Reisenburg International Symposium, Thyroid 2000: From bench to bedside, from
gene to patient, Reisenburg, Germany: “Nuclear receptors in control of lipid
homeostasis”. June, 2000.
277.
ASPET, Burroughs Wellcome Fund Lecture, Boston, USA: “Estrogen receptor  - A
paradigm shift in understanding estrogen action”. June, 2000.
278.
7th Nordic Nutrition Congress, Mariehamn, Åland: “ Nutrients in control of gene
regulation”. June, 2000.
279.
Hormone-dependent Cancers and Nuclear Receptors, Saitama, Japan: “Role of
estrogen receptor  and  in steroid hormone-dependent tissues and cancers”. June,
2000.
280.
International Meeting on Women’s Health and Menopause, NIH, Washington D.C., USA:
“Physiological Role of Estrogen and Estrogen Receptors”. July, 2000.
281.
14th Ecdysone Workshop, Rapperswil, Switzerland: “On a paradigm shift in our
understanding of estrogen mechanism of action: Discovery of estrogen receptor “. July,
2000.
33
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
282.
VIth International Conference on Hormones, Brain and Behavior & The Society for
Behavioral Neuroendocrinology, Madrid, Spain: Keynote Lecture “Recent developments
in our understanding of estrogen action: Estrogen Receptor “. August, 2000.
283.
FEBS Advanced Study Institute, International Summer School on New dimensions in the
regulation of gene expression, Spetses, Greece: “Novel mechanisms in estrogen
signalling” and “Nuclear receptor regulated lipid homeostasis”. August, 2000.
284.
Third Annual Symposium on “Functional genomics – the human touch”, Gothenburg,
Sweden: “Potential of genomics for diagnosis and drug development – the example of
the steroid receptor superfamily”. August, 2000.
285.
EUROTOX 2000, XXXVIII European Congress of Toxicology, London: “The role of the
ER in oestrogen mediated carcinogenesis”. September, 2000.
286.
A Joint International Symposium arranged by the Center for Biotechnology (CBT),
Karolinska Institutet and EUROSTERONE in collaboration with the Summer University of
Southern Stockholm, “Nuclear Receptors in Health and Disease”, Huddinge, Sweden:
“Estrogen receptor  - A paradigm shift in understanding estrogen action”. September,
2000.
287.
Pannon Symposium, Tissue-selective estrogen action: from basic science to the clinical
practice, Pécs, Hungary: Keynote lecture “Estrogen receptor-: A paradigm shift in
understanding estrogen action”. September, 2000.
288.
BioTech Forum, Älvsjömässan, Stockholm, Sweden: “Rational drug design based on
steroid hormones and their receptors and the interaction between academic research
and KaroBio AB”. October, 2000.
289.
Cinquièmes Journées Européennes de la Sociéte Francaise de Gynécologie, Paris,
France: “Estrogen receptors”. October, 2000.
290.
Cardiovascular Disease and Hormone Replacement Therapy, IMS Workshop Royal
Society of Medicine, London, U.K.: “Estrogen receptors”. October, 2000.
291.
E.hormone 2000 – the cutting edge of endocrine disrupter research, Tulane University,
New Orleans, U.S.A.: “Estrogen receptor  - a paradigm shift in our view on estrogen
signaling and endocrine disruption”. October, 2000.
292.
Keynote Lecture at Hormones and cancer 2000 and Aromatase 2000 and the 3rd
generation, Port Douglas, Queensland, Australia: “Estrogen receptor  – a paradigm shift
in understanding estrogen action”. November, 2000.
293.
Keynote Lecture at Garvan Symposium “Estrogens & Womens Health”, Sydney,
Australia: “Mechanisms of estrogen action: the role of ERbeta”. November, 2000.
294.
Keynote Lecture at Steroid receptor and cell signaling, Cincinnati, University of
Cincinnati, USA: “Estrogen receptors and control of proliferation”. November, 2000.
295.
European Medal Lecture. 191st Meeting of the Society for Endocrinology, London, U.K.:
“Estrogen receptor  - a paradigm shift in understanding estrogen action”. November,
2000.
296.
23rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA: “ER
and ER : “The Yin-Yang principle of estrogen action”. December, 2000.
34
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
297.
1st Meeting of the Network “Environmental Estrogens and their Effects in Health and
Disease”, Athens, Greece: “The mechanism of action of estrogens – The role of ER“.
January, 2001.
298.
Mayo Clinic, Rochester, USA: “Estrogen Receptor Beta – a Breakthrough in
Understanding Estrogen Signaling”. February, 2001.
299.
II International Symposium of the Portuguese Menopause Society, Menopause:
Hormones and Cancer, Lisbon, Portugal: “Estrogen receptors and Breast Cancer”.
March, 2001.
300.
Disorders of the Prostate. Advances in Basic Mechanisms and the Implications for
Clinical Management, Castres, France: “Oestrogen receptor beta knock out leads to
hyperplasia in the ventral prostate”. March, 2001.
301.
Experimental Biology 2001, The American Association of Immunologists, Orlando,
Florida, USA: “Molecular aspects of estrogen receptors alpha and beta”. March/April,
2001.
302.
5th Annual Frontiers in Estrogen Action, County Clare, Ireland: “ER biology: New
Frontiers”. April, 2001.
303.
EMBO Workshop on Nuclear Receptor Structure and Function, Erice, Italy: “Novel
aspects on estrogen signaling”. May, 2001.
304.
4th International Symposium on Women’s Health and Menopause, Washington DC, USA:
“Estrogen signaling – New Paradigms”. May, 2001.
305.
Eukaryotic Transcription: From mechanism to function, Turku, Finland: “Estrogen
Receptors”. June, 2001.
306.
Neuroendocrine Workshop on Hormones, Mood and Behavior, Breckenridge, Colorado,
USA: “Estrogen receptor ”. June, 2001.
307.
FASEB Summer Research Conference Program “Steroids and Bone”, Whitefish,
Montana, USA: “ER-ER interplay in estrogen action”. June, 2001.
308.
A Eurosterone Thematic Conference: Steroid signalling: New Frontiers, Edinburgh,
Scotland: “New Frontiers in estrogen signalling”. June, 2001.
309.
XIth International Congress on Genes, Gene Families and Isozymes; Stockholm,
Sweden: “The nuclear receptor super gene family – developments and highlights”.
June/July, 2001.
310.
17th Annual meeting of the European Society of Human Reproduction and Embryology,
Lausanne, Switzerland: “Transgenic models in reproductive research”. July, 2001.
311.
Bone and Tooth Society, Annual Meeting, Warwick, UK: “Regulation of transcription by
different estrogen receptors”. July, 2001.
312.
15th Annual Symposium on The Long-Term Effects of Estrogen Deprivation, Bermuda:
“Phenotypes of ER knockout mice”. July, 2001.
313.
7th International Summer School Behavioral Neurogenetics, Lake Erken, Norrtälje,
Sweden: “A tale of two estrogen receptors”. July, 2001.
35
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
314.
IMCB, Singapore: “New paradigms in estrogen signalling – estrogen receptor beta” and
“LXRalfa and LXRbeta – two novel and important regulators of cholesterol homeostasis”.
July, 2001.
315.
Nuclear Receptors – Recent Developments, Oslo, Norway: “New paradigms in estrogen
signalling”. August, 2001.
316.
XXIII Congress of the European Society of Cardiology together with the 36th Annual
General Meeting of the Association for European Paediatric Cardiology, Stockholm:
“Update on estrogen receptors”. September, 2001.
317.
The Charles Brenton Huggins Memorial Symposium, Chicago, USA: “ER-beta: A
receptor with many faces”. September, 2001.
318.
XXVIth European Symposium on Hormones and Cell Regulation, Mont Ste Odile: “On
the role of estrogen receptor beta in reproduction” and “LXRs”. September, 2001.
319.
Benzon Symposium No 48: Drug Metabolism Regulation and Importance, Copenhagen:
“Molecular mechanisms of CYP induction”. September, 2001.
320.
Medicon Valley BioConference 2001, Copenhagen, Denmark: “Nuclear receptors as
target for drug development – A scientifically and commercially hot area that may serve
as a role model for a new paradigm in academic research”. September, 2001.
321.
8th ICEM, Shizuoka, Japan: Plenary lecture “Nuclear receptor – environment
interactions”. October, 2001.
322.
Science in Japan Forum, Stockholm: “Recent advances in understanding nuclear
receptors”. October, 2001.
323.
3rd Biennial International Meeting of the Flemish Gynaecological Oncology Group,
Endocrine treatment and prevention of breast and gynaecological cancers, Brussels,
Belgium: “The latest on ER beta in gynaecological and breast cancers”. November,
2001.
324.
2001 Workshop on Genomic vs non-genomic steroid action: Encountered or unified
views, Madrid, Spain: “The nuclear-receptor interacting proteins”. December, 2001.
325.
First International Nuclear Receptor Meeting in Japan, Kyoto, Japan: “An update on the
biology of estrogen receptor beta”. March, 2002.
326.
2nd Annual Lectureship inWomen’s Health Research “From estrogen receptors to
management of menopause”, Washington, USA: “Estrogen receptor – A multifaceted
player”. March, 2002.
327.
Lecture at Chinese Academy of Medical Sciences, Beijing, China: “Recent advances in
our understanding of estrogen signalling pathways”. April, 2002.
328.
6th Annual Frontiers in Estrogen Action, Amelia Island, Florida: “Update on the biology of
ER”. April, 2002.
329.
7th Congress of the European Society of Contraception, Genova, Italy: “Steroid
receptors”. April, 2002.
330.
Keystone meeting on Nuclear Receptor Superfamily, Snowbird, Utah, USA: “On the role
of ERbeta in the CNS”. April, 2002.
36
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
331.
Swiss National Research Programme (NRP) 50 “Endocrine Disruptors”, Zürich,
Switzerland: “Steroid receptors and transcription mechanisms: action of endocrine
disruptors”. April, 2002.
332.
Hormones and Genome: Basic research towards improvement of diagnostic and
therapeutic medicine, Blaubeuren/Ulm, Germany: “New paradigms in estrogen signaling
– ER as the Deus ex machina”. May, 2002.
333.
Fourth Annual Symposium on Developmental & Molecular Toxicology, Development and
Genetic Aspects of Breast Cancer, Madison, Wisconsin, USA: “Estrogen signaling – a
matter of thesis and antithesis”. June, 2002.
334.
10th World Congress on the Menopause, Plenary lecture, Berlin, Germany: “Estrogen
receptor – a multifacetted player”. June, 2002.
335.
XIVth World Congress of Pharmacology, Plenary lecture, San Fransisco, USA: “Estrogen
receptors”. July, 2002.
336.
Conférence du Centre de recherche, Quebec, Canada: “Estrogen receptor  - an
important and multifacetted player in estrogen signaling”. July, 2002.
337.
National Cancer Centre, Tokyo, Japan: “Novel aspects on estrogen signaling and
hormone dependent cancer”. July, 2002.
338.
14th International Symposium on Microsomes and Drug Oxidations (MDO 2002),
Sapporo, Japan: “Crosstalk between PPAR and LXR: Two major regulators of lipid
metabolism”. July, 2002.
339.
Summer School/Bregenz 2002, “From genes via endocrine models to patients”, Bregenz,
Austria: “ER , ER and more” and “ED interactions with ER and ER”. July, 2002.
340.
International Summer School on Neurotrophin and Nuclear Receptors: From Molecules
to Behaviour, Lake Erken, Norrtälje, Sweden: “Estrogen receptors: alpha and beta”.
August, 2002.
341.
Nuclear Receptors 2002 - A Joint International Symposium arranged by the Center for
Biotechnology (CBT), Karolinska Institutet in collaboration with the Summer University of
Southern Stockholm, Huddinge, Sweden: “ERbeta as a regulator of cellular
proliferation”. August, 2002.
342.
The 5th International Congress of Neuroendocrinology, Bristol, U.K.: “Genomic and nongenomic actions of steroids”. August/September, 2002.
343.
Nuclear receptors and disease, Göteborg, Sweden: “Sterol homeostasis controlled by
nuclear receptors”. September, 2002.
344.
30th Conference of the European Teratology Society in conjunction with the symposium
Adverse effects of endocrine disruptors, Hannover, Germany: “Mechanisms of endocrine
signaling”. September, 2002.
345.
26th Congress of the Société Internationale d’Urologie, Stockholm, Sweden: State-of-theArt-Lecture: “The role of estrogen-receptor beta in control of prostate growth”.
September, 2002.
346.
ENEA 2002 Münich, 10th Meeting of the European Neuroendocrine Association, Münich,
Germany: “Estrogen receptors”. September, 2002.
37
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
347.
European Respiratory Society, Annual Congress 2002, Stockholm, Sweden:
“Glucocorticoid receptors and cell signalling (overview talk)”. September, 2002.
348.
Molecular mechanisms as targets in prostatic diseases, Liverpool, UK: “The role and
function of ER-beta in the development of prostate cancer”. September, 2002.
349.
2nd European Congress of Andrology, Malmö, Sweden: “A novel endocrine pathway in
the prostate, ER, AR, 5 -androstane-3, 17-diol, and CYP7B1, regulates prostate
growth”. September, 2002.
350.
International Society for the Study of Women’s Sexual Health, Annual Meeting 2002,
Vancouver, Canada: State of the Art Lecture, “New paradigms in understanding estrogen
signaling”. October, 2002.
351.
Tianjin TEDA Watson Biopark Development Conference, Tianjin, China: “Recent
advances in our understanding of nuclear receptor action”. October, 2002.
352.
e.hormone 2002, New Orleans, USA: “Environmental signals: Multiple receptors &
multiple inputs”. October, 2002.
353.
Women’s Health Special Interest Group (WHSIG), NIH; Washington, USA: “Estrogen
receptors – from molecular biology ot therapeutics”. November, 2002.
354.
Burroughs Wellcome Fund Visiting Professorship In the Basic Medical Sciences,
University of Texas Medical Brand School of Medicine, Houston, Texas, USA: “A new
paradigm in estrogen signaling provided by the dynamic interplay between ERalpha and
ERbeta”. November, 2002.
355.
Biomedicum Helsinki Seminars: Frontiers in Medicine, Helsinki, Finland: “Nuclear
receptors and regulation of cholesterol homeostasis”. November, 2002.
356.
Fourth Amazon Project Conference, Innaovative Strategies and Perpectives in Cancer
Care, Palermo, Italy: “The novel estrogen receptor beta – possible implications for breast
cancer”. November, 2002.
357.
British Pharmacological Society Wintermeeting, Nuclear receptors: targets for new
therapies, Brighton, U.K.: “Oestrogen receptors”. January, 2003.
358.
Symposium Regulation of cell signalling by estrogens and phytoestrogens, McDowell
Lecture in Physiology, London, U.K.: “Estrogens – how do they work?”. January, 2003.
359.
Distinguished Guest for 2003 in the Molecular and Cellular Biology Department at Baylor
College of Medicine, Houston, Texas, U.S.A.: “A new look on estrogen signaling”.
February, 2003.
360.
Ernst Schering Research Foundation, Workshop 46, New molecular mechanisms of
estrogen action and their impact on future perspectives in estrogen therapy, Berlin,
Germany: “Novel functions of ER as revealed by studies of phenotypes of ER K.O.mice”. March, 2003.
361.
International Group on Insulin Secretion, Novel Factors in the Regulation of -cell
function, St. Jean-Cap-Ferrat: Keynote Lecture, “Frontiers in nuclear receptors
research”. March, 2003.
362.
On Target 2010: The Future of Medicines, Stockholm, Sweden: “The academic research
perspective”. April, 2003.
38
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
363.
Chairman at the 7th Annual Frontiers in Estrogen Action, The Homestead, Hot Springs,
Virginia. April, 2003.
364.
6th European Congress of Endocrinology, Lyon, France: Plenary Lecture, “Role of
estrogen receptors: lessons from knock-out mice”. April, 2003.
365.
Calcified Tissue International, Rome, Italy: Plenary Lecture, “Modulation of estrogen
action by ER isoforms”. May, 2003.
366.
Novel approaches to treatment in hormone-sensitive breast cancer, London, U.K.:
“Elucidation of ER function in breast cancer”. May, 2003.
367.
Utrecht Graduate School of Developmental Biology, Utrecht, The Netherlands: “New
paradigms in estrogen signaling”. June, 2003.
368.
2nd Dutch Endo-Neuro-Psycho meeting, Doorwerth, The Netherlands: Marius Tausk
Lecture, “New paradigms in estrogen signaling”. June, 2003.
369.
EMBO Conference, Biology of Nuclear Receptors, Villefranche-sur-Mer (Nice), France:
“Antiproliferative actions of estrogen receptor ”. June, 2003.
370.
Special Symposium on estrogen receptors, Los Angeles, USA: “Estrogen receptor-beta
– A paradigm shift in understanding estrogen signaling”. June, 2003.
371.
Allosteric Mechanisms of Signal Transduction, Paris, France: “Estrogen signaling –
importance of conformational changes in estrogen receptor action”. June, 2003.
372.
European Code against cancer, Clinical Cancer Research in Europe, Milan, Italy:
“Oestrogen signaling and cancer”. June, 2003.
373.
Fourth International Symposium on Hormonal Carcinogenesis, Valencia, Spain: “A novel
mechanism for control of prostate growth”. June, 2003.
374.
Special FEBS 2003 Meeting on Signal Transduction; Signal transduction: from
membrane to gene expression, from structure to disease, Brussels, Belgium: Datta
Lecture “Update on estrogen signaling”. July, 2003.
375.
19th Ernst Klenk Symposium, Transcriptional and other regulatory mechanisms of lipid
metabolism, Cologne, Germany: “Some phenotypes of LXR KO mice”. July, 2003.
376.
HLSC 2nd event, Hormones and Genome, Molecular Mechanisms in Metabolic Diseases:
Obesity, Diabetes Type 2, Lipid disorders and Atherosclerosis – Basic Science towards
Clinical Application, Ulm, Germany: “Some phenotypes of LXR KO mice”. July, 2003.
377.
Summer School on Endocrinology, Bregenz, Austria: “Estrogen receptors and metabolic
syndrome”. July, 2003.
378.
Nobel Conference No 40, Transcriptional control of lipid homeostasis, Stockholm,
Sweden: “LXR and control of lipid homeostasis”. August, 2003.
379.
FEBS Advanced Study Institute, International Summer School, From transcription to
physiology: Regulation of gene expression and protein function in an integrated context,
Spetses, Greece: “Mechanisms of estrogen action” and “Insight into the biology of
estrogen and Liver X receptors by studying knock-out mice”. September, 2003.
380.
8th Nottingham International Breast Cancer Conference, Nottingham, U.K.: “Development
and an overview of ER“. September, 2003.
39
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
381.
Lecture at the University of Mainz, Institute of Toxicology, Mainz, Germany: “New views
on estrogen signaling”. September, 2003.
382.
Rudbeck seminars, Uppsala University: “New understanding of estrogen action”.
September, 2003.
383.
The Endocrine Society: The Role of Nuclear Receptors in Cardiovascular Disease, San
Diego: “Estrogens and the Immune System: Novel Lessons from ERalfa and ERbeta KO
Mice”. October, 2003.
384.
The 2nd International Symposium of Gender Related Medicine at Centre of Gender
Related Medicine, Karolinska Institutet, Stockholm, Sweden: “New paradigms of
estrogen signalling – genderaspects”. October, 2003.
385.
Maturitas Master Class, Lisbon, Portugal: “Steroid receptors” and “Specific alpha and
beta ER-ligands”. October, 2003.
386.
International School of Medical Science, 117th Advanced Course on Signal Transduction
and Communication in Cancer Cells, Erice, Italy: “Estrogen Receptor Beta in
Development and Cancer”. October, 2003.
387.
Eleventh Annual Nuclear Receptor Symposium, Nuclear Receptors: Discovery, Biology,
and Therapy, Stevenage, U.K.: “Novel views on estrogen signaling”. October, 2003.
388.
13th Annual Meeting of the Dutch Society for Calcium and Bone Metabolism, Zeist, The
Netherlands: “Estrogen signaling – a case of yin and yang”. October, 2003.
389.
The 6th U.S.- Taiwan Neuroscience Symposium, Estrogen actions in the brain, New
Orleans, USA: “ERbeta in the nervous system”. November, 2003.
390.
Bengt E Gustafsson Symposium, Microbial Ecology in Health & Disease, Born germfree
– microbial dependent, Stockholm: “Metabolism”. November, 2003.
391.
Jensen Symposium, Nuclear Receptors and Endocrine Disorders, Cincinnati, USA:
“Estrogens and diseases of brain and the immune system”. December, 2003.
392.
Boosting Innovation from Research to Market, Bryssel, Belgium: “Academy-industry
interactions at the Novum Campus in Stockholm”. December, 2003.
393.
The Biotechnology, the Capital and the Brain – The Mixing Chemistry of Bioeconomy,
Beijing, China: “Nuclear Receptors – From Academia to Commercial Application”.
December, 2003.
394.
Rui Jin Hospital, Shanghai, China: “Yin-yang of estrogen signaling”. December, 2003.
395.
Workshop Nuclear Receptors, Leiden, Netherlands: “Estrogen receptor-beta – a
multifunctional transcription factor”. January, 2004.
396.
Updates in Infertility Treatment, Marco Island, Florida, USA: “Novel functions of estrogen
receptor beta”. January, 2004.
397.
A. I. Virtanen Institute Research Seminars, Kuopio, Finland: “A new look upon estrogen
signaling”. January, 2004.
398.
Keystone Symposia on Nuclear Receptors: Orphan Brothers, Keystone Resort,
Colorado: “New roles of estrogen receptor ”. February, 2004.
40
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
399.
Umeå University: “Estrogen signaling – an area of rapid development and relevance”.
March, 2004.
400.
ERPM 2004, Stéroïdes sexuels: le point sur l’action des estrogènes et des progestatifs.
Montpellier, France: “Effects of ER on the CNS”. March/April 2004.
401.
55. Mosbacher Kolloquium: How nutrients influence gene activity, Mosbach, Baden,
Germany: “On the role of estrogen receptors and liver X receptors in lipid metabolism”.
April, 2004.
402.
15th Symposium on Growth Hormone and Endocrinology, Malta: “Estrogen receptor beta
regulates epithelial cell differentiation in the mouse ventral prostate”. April, 2004.
403.
European Atherosclerosis Society, 74th EAS Congress, Seville, Spain: “Estrogen
signaling and the cardiovascular system – some new angles”. April, 2004.
404.
5th International Symposium on Women’s Health and Menopause, Florence, Italy: “ER A multifunctional regulator of women’s health”. April, 2004.
405.
Hormones and the Genome, HLSC 3rd event, Endocrine malignancies and autoimmunity,
Molecular biological events and targets for clinical application, Ulm, Germany: “Estrogen
signaling and the immune system – new excitements”. April, 2004.
406.
Nuclear receptors, transcription, and cancer symposium, University of Virginia, Virginia,
USA: “A new look at estrogen signaling”. May, 2004.
407.
Eli Lilly, Indianapolis, Illinois, USA: “Recent excitements in estrogen signaling”. June,
2004.
408.
Breast Cancer Meeting, New Orleans, USA: “New vistas in estrogen signaling”. June,
2004.
409.
Environmental and Endocrine Signaling, A Satellite Symposium preceding the annual
Society of Endocrinology Meeting, New Orleans, USA: “Nuclear receptors as signal
sensors”. June, 2004.
410.
Workshop “Food safety and quality: state of research in the Southern Mediterranean
Agronomic Studies”, Bari, Italy: “Projet CE: CASCADE”. July, 2004.
411.
MDO 2004, 15th International Symposium on Microsomes and Drug Oxidations:
Chemical biology in the postgenomic era; new approaches and applications, Mainz,
Germany: “Role of P450 in steroid hormone action”. July, 2004.
412.
Seventh International Symposium on Neurobiology and Neuroendocrinology of Aging,
Bregenz, Austria: “The role of the estrogen receptor 
413.
Summer School on Endocrinology, Nuclear Receptors, Endocrine Disruptors and
Metabolic Effects, Bregenz, Austria: “ER and immunology”. July, 2004.
414.
37th Annual Meeting of the Society for the study of reproduction, Vancouver, British
Columbia, Canada: “Targeting cancers by estrogens and its analogs”. August, 2004.
415.
XVIII World Congress International Society for Heart Research, Brisbane, Australia:
Estrogen derivatives in cardiovascular disease-old questions, new answers; “New
paradigms in estrogen signaling with particular reference to cardiovascular function”.
August, 2004.
41
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
416.
XVIIIth International Symposium on Medicinal Chemistry, Copenhagen, Denmark:
“Recent excitements in drug development based on novel insights in estrogen signaling”.
August, 2004.
417.
UT Forum 2004 in Sweden, Medical and Life Sciences, “Molecular Medicine and Its
Recent Advances”, Stockholm, Sweden: “New vistas in estrogen signaling: Therapeutical
implications”. August, 2004.
418.
ESPE 18th Summer School 2004, “Estrogen receptor”, Ramsach, Switzerland: “Estrogen
receptor”. September, 2004.
419.
55th Annual Meeting of the European Association for Animal Production, Bled, Slovenien:
“Estrogen signaling in the mammary gland”. September, 2004.
420.
43rd Annual Meeting of the European Society for Pediatric Endocrinology, Basel,
Switzerland: “New paradigms in estrogen signaling and their clinical implications”.
September, 2004.
421.
CASCADE Summer School on Nuclear Receptors, ENS Lyon, Lyon, France: “LXR and
ER signaling”. September, 2004.
422.
Inaugural COST 926 Conf. Eur. Workshop on Cellular Responses to bioactive plant
compounds – implications for human health, Budapest, Hungary: Keynote lecture
“Estrogen signaling and cancer prevention”. September/October, 2004.
423.
Nuclear Receptors 2004 - An International Symposium arranged by the Center for
Biotechnology (CBT), Karolinska Institutet, Huddinge, Sweden: “Estrogen signaling in
new light”. October, 2004.
424.
Annual Bristol-Myers Squibb/Mead Johnson Nutrition Award Symposium, New York,
USA: “New paradigms in estrogen signalling”. October, 2004.
425.
China TEDA Bioforum, Tjianjin, China: “Nuclear Receptors, A rapidly developing field”.
October, 2004.
426.
e.hormone 2004, Tulane University, New Orleans, USA: “New surprises in estrogen
signaling”. October, 2004.
427.
Nuclear Receptors and Genomic Medicine, Saitama Medical School, Saitama, Japan: “A
new look at estrogen signaling”. November, 2004.
428.
National Cancer Center Research Institute, Tokyo, Japan: “ER and cancer”. November,
2004.
429.
Tokyo University, Inst. of Molecular and Cellular Biosciences, Japan: “Novel concepts in
estrogen signaling open up new therapeutical possibilities in many areas”. November,
2004.
430.
Biomedicum Helsinki, Helsinki, Finland: “New paradigms in estrogen signaling open up
novel pharmaceutical approaches for several diseases”.
431.
DG RTD Workshop: Mechanisms of organ specific ageing, Brussels, Belgium: “Steroids
and ageing”. December, 2004.
432.
China University of Science & Technology, Hefei, China: “New excitements in estrogen
signalling”. December, 2004.
42
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
433.
Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China: “Estrogen
signalling in the CNS”. December, 2004.
434.
Cascade 1st Annual Meeting, Chemical Contaminants in Food: Proposals for Scientific
Research, Orvieto, Italy: “Nuclear receptors – an overview”. January, 2005.
435.
Enhanced International Collaboration in the Field of Endocrine Disrupters: How to do it in
practice? Workshop Organised by the European Commission’s Research DirectorateGeneral, Brussels, Belgium: “Integration of international organisations in CASCADE
network of excellence: Chemicals as contaminants in the food chain: a network of
excellence for research, risk assessment, education and information”. January, 2005.
436.
Keystone symposia on Hormonal Regulation of Tumorgenesis, Monterey, California,
USA, February 2005: “Antiproliferative actions of ER”. February, 2005.
437.
Keynote Lecture at Symposium in the honor of Dr. Paul van der Saag, Utrecht, The
Netherlands: “Nuclear receptors during two centuries”. March, 2005.
438.
2nd Ernst Knobil Memorial Lecture, San Diego, USA: “Estrogen receptor beta – a
multifunctional regulator”. April, 2005.
439.
8th Frontiers in Nuclear Receptor, Phoenix, Arizona, USA: “Estrogen signaling – New
mechanisms”. April, 2005.
440.
40th
antiproliferative drugs”. May, 2005.
441.
The fifth annual meeting of the Network for functional studies in mice, Stockholm,
Sweden: “Lessons learnt from ERbeta and LXRbeta KO mice”. May, 2005.
442.
62nd KSBMB Annual Meeting in 2005 – From mechanism to functions, Seoul, South
Korea: Keynote Lecture “Estrogen receptor  - a novel tumor suppressor gene?”. May,
2005.
443.
Nobel minisymposium “Sex differences in the human brain, their mechanisms and
implications”, Stockholm, Sweden: “ERbeta and CNS function”. May, 2005.
444.
6th Puberty Conference, Evian, France: “Precocious puberty and early ovarian failure in
CYP7B1 knockout mice”. May, 2005.
445.
ENDO 2005, San Diego, USA: “Estrogen receptor beta”. June, 2005.
446.
Engebretson symposium on drug discovery and development in cancer experimental
therapeutics, Minnesota, USA: Keynote lecture “Recent excitements in drug
development based on novel insights in estrogen signalling”. June, 2005.
447.
8th Int. Congress of Andrology and 22nd Annual Meeting of Korean Andrological Society,
Men’s health –
antiproliferative principle in the prostate”. June, 2005.
448.
The Third International Symposium on the Molecular Biology of Breast Cancer, Molde,
449.
CASCADE Open Forum, The chemical pollutants in our food, Visby, Sweden: “Hormonedisrupting chemicals – what are they?”. July, 2005.
43
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
450.
Descartes Prize Nominee Meeting, Brussels: “Pathfinder – a Euorpean network for
research on nuclear receptors”. July, 2005.
451.
Hormone Action in Development & Cancer, Gordon Research Conference, Mount
Holyoke, South Hadley, USA,: “Antiproliferative actions of Erbeta – mechanisms and
possible pharmaceutical applications”. July, 2005.
452.
Eli Lilly, Indianapolis, July 2005: “ER
453.
Inje University, Busan, Korea, July 2005,
1. “The liver X receptor”
2. “Recent advances in understanding estrogen action”
3. “Karolinska Institutet and Biomedical Science Park in Sweden”
454.
Int. Workshop on Physical Sciences at the Microscale and First IAAC meeting of HFNL,
Hefei and Huang shan, China: “Mechanisms of action of female sex hormones”. August,
2005.
455.
46th International Conference on the Bioscience of Lipids, Ajaccio, Corsica: “The role of
LXR in the liver, adipocytes and nervous system”. September, 2005.
456.
Center for Molecular Medicine, University of Cologne, Cologne, Germany: “Estrogen
receptor beta – a new paradigm in estrogen signaling”. September, 2005.
457.
EMBO Conference, Nuclear Receptor: From Chromatin to Disease, Lake Garda, Italy:
“ERbeta – an antiproliferative principle”. September/October, 2005.
458.
1 Simpósio Mulher Sempre Mulher, Hormones and Breast Estrogen Receptor Beta and
SERM’s, Lisbon, Portugal: “Estrogen receptor beta in breast cancer”. October, 2005.
459.
Int. symp. Endocrine disrupters – Occurrence in the bioenvironment and possible effects
in animals and humans, Oslo, Norway: “New surprises in estrogen signalling”. October,
2005.
460.
Fourth Annual AACR Int. Conf., Frontiers in Cancer Prevention Research, Baltimore,
USA: “Estrogen receptors and breast cancer”. October/November, 2005.
461.
China TEDA Bioforum, Advances in Life Sciences, Tianjin, China: “Estrogen receptor 
in breast cancer”. November, 2005.
462.
The MTC Annual Talks 2005, Nobel Forum, KI, Stockholm, Sweden: “On the role of
estrogen receptor  in the immune system”. November, 2005.
463.
University of Kentucky, Lexington, USA: “A new look on estrogen signaling: The role of
estrogen receptor “. January, 2006,
464.
Yale University School of Medicine, Pharmacology Seminar Series, New York, USA: “A
new look at estrogen signaling”. January, 2006.
465.
University of Milan, EWA – Estrogens and Women Aging, Milano, Italy: “Erbeta and
menopause”. January, 2006.
466.
The 1st World Congress on Gender-Specific Medicine, “Men, Women, and Medicine: A
New View of the Biology of Sex/Gender Differences and Aging”, Berlin, Germany:
“Estrogen receptors in the brain”. February, 2006.
- a multifunctional regulator”. July, 2005.
44
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
467.
European Society for Clinical Investigation, 40th Annual Scientific Meeting, Prague,
Czech Republic: Plenary lecture, “Clinical use of estrogen receptor beta”. March, 2006.
468.
Keystone Symposia, Nuclear Receptors: Orphan Brothers, Banff, Alberta, Canada:
“Biology of estrogen receptor  - New insights”. March, 2006.
469.
CASCADE 2nd Annual Meeting, St Malo, France: “CASCADE – past and future”. March,
2006.
470.
EUROPT(R)ODE VIII, Tübingen, Germany: "Nuclear receptor signaling – a gold mine for
development/application of novel techniques for studies on molecular interactions“. April,
2006.
471.
9th Frontiers in Nuclear Receptor Action, Sanibel Harbour, Ft Myers, Florida, chairman.
April, 2006.
472.
41st Annual meeting of The European Association for the study of the liver, Vienna,
Austria: “Liver X receptor”. April, 2006.
473.
Yale University School of Medicine, OB GYN Seminar Series, New Haven, USA:
“ERbeta scientific visions translate to clinical uses”. May, 2006.
474.
132nd Advanced Course on : Estrogens and Human Diseases, Erice, Italy: “Recent
advances in estrogen signaling”. May, 2006.
475.
5th Gordon Research Conference on Environmental Endocrine Disruptors, Il Ciocco,
Barga, Italy: “Steroid receptors, crosstalk and potential endocrine disruption”. June,
2006.
476.
Symposium “Neue Erkenntnisse in der Frauenhelikunde – Gesundheit, Hormone und
Soja”, Vienna, Austria: “Estrogen action – two different signaling pathways”. June, 2006.
477.
5th Int. Congress of Pathophysiology, Beijing, China: “ER  - a multifunctional nuclear
receptor”. June/July, 2006.
478.
Second Military Medical University, Shanghai, China: “New discoveries in estrogen
signaling translate into clinical medicine”. July, 2006.
479.
15th World Congress of Pharmacology, Beijing, China: “Recent advances in estrogensignaling and new sites for pharmacological interventions”. July, 2006.
480.
Academy of Military Medical Sciences (AMMS), Beijing, China: “Estrogen receptor  - a
new drug target”. July, 2006.
481.
BioScience 2006, Glasgow, UK: “New developments in oestrogen signalling”. July, 2006.
482.
Bregenz Summer School on Endocrinology: Nuclear Receptors in Health & Disease,
Bregenz, Austria: Plenary Lecture: “Recent Highlights in Estrogen Signaling”. August,
2006.
483.
AP ECHO, Asia-Pacific Education Center of Hematology/Oncology and Translational
Medicine, Shanghai, China: “Nuclear receptors in disease”. August, 2006.
484.
12th International Congress on Hormonal Steroids and Hormones & Cancer, Athens,
Greece: “Regulation of prostate growth by estrogen receptors 
”. September,
2006.
45
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
485.
Nuclear Receptors 2006 - An International Symposium arranged by the Center for
Biosciences, Karolinska Institutet, Huddinge, Sweden: “Role of estrogen receptor 
(ER) and liver X receptor  (LXR) in the central nervous system”. September, 2006.
486.
The Institute of Cancer Research, Breakthrough Breast Cancer Research Centre,
London, U.K: “New paradigms in estrogen signaling rapidly translate into clinical
medicine”. September, 2006.
487.
11th Annual Meeting of the European Council for Cardiovascular Research (ECCR), La
Colle sur Loup, Nice, France: “The estrogen receptor and cardiovascular diseases”.
September, 2006.
488.
3rd International Greek Biotechnology Forum, Athens, Greece: Honorary Lecture
“Estrogen receptor beta – a new paradigm in estrogen signaling”. October, 2006.
489.
Founding Symposium, International Graduate School in Molecular Medicine Ulm, Ulm,
Germany: “Paradigm shifts in our understanding of estrogen signaling following the
discovery of estrogen receptor beta”. October, 2006.
490.
Jilin University, Department of Pathology, Changchun, China: “Novel paradigms in
estrogen signaling in health and disease”. October, 2006.
491.
Jilin University, Shool of Public Health, Changchun, China: “Diet and genes”. November,
2006.
492.
Duodecim Symposium on Nuclear receptors in health and disease, Turku, Finland:
“Novel actions of estrogen via estrogen receptor beta”. November, 2006.
493.
The 10th Meeting Hirosaki International Forum of Medical Science, Hirosaki, Japan:
“Novel paradigms in estrogen signaling in health and disease”. November, 2006.
494.
The National Cancer Center Research Institute, Tokyo, Japan: “Estrogen receptor  - a
multifunctional receptor and a promising drug target”. November, 2006.
495.
International Conference on Food Contaminants and Neurodevelopmental disorders,
Valencia, Spain: “The role of ERalpha and beta in endocrine disruptors toxicity”.
December, 2006.
496.
Second meeting of the project estrogen in women ageing (EWA), Madrid, Spain: “The
aromatase KO mouse – an appropriate model for menopause?”. January, 2006.
497.
Keystone Symposia, Reproduction: Advances and Challenges, Santa Fe, New Mexico,
USA: “Role of estrogen receptor beta in reproduction”. February, 2006.
498.
Global LAM Summit, Stockholm, Sweden: “Estrogen receptor beta – a novel
antiproliferative transcription factor”. February, 2007.
499.
Working session on Hormonoresistance in breast cancer, Paris, France : “The estrogen
receptor beta”. March, 2007.
500.
Society for Endocrinology BES 2007, Birmingham, UK: “Estrogen receptors in
development”. March, 2007.
501.
Annual Meeting of the Swedish Society for Study of Reproduction, SSSR, Uppsala,
Sweden: “Dramatic changes in understanding of estrogen action”. March, 2007.
46
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
502.
Keystone Symposia, Nuclear Receptor Pathways to Metabolic Regulation, Sheraton
Steamboat Resort, Steamboat Springs, Colorado, USA: “Role of estrogen signaling in
the metabolic syndrome”. March, 2007.
503.
CASCADE 3rd Annual Meeting, Helsinki, Finland: “CASCADE past and future”. April,
2007.
504.
10th Frontiers in Nuclear Receptor Action, Georgia, USA: “New roles for estrogen
receptor  in the developing and adult CNS”. April, 2007.
505.
9th European Congress of Endocrinology, Budapest, Hungary: “Recent developments in
nuclear receptor action”. April/May, 2007.
506.
Nuclear Receptors: Stucture and Function in Health and Disease, Gardone Riviera, Lake
Garda, Italy: “LXRbeta – A link between beta-sitosterol and ALS-Parkinson’s dementia”.
May, 2007.
507.
University Hospital UZ Gasthuisberg, Leuven, Belgium: “Estrogen receptor beta – a
revolutionary in estrogen signaling”. May, 2007.
508.
Digestive Disease Week 2007, Washington, USA: “Estrogen signaling in the brain and
gut”. May, 2007.
509.
10th Conference in Advanced Medicinal Chemistry, Thessaloniki, Greece: “A new era in
devlopment of estrogenic pharmaceuticals: Alfa-estrogenic and beta-estrogenic drugs”.
May, 2007.
510.
6th Dutch Endo-Neuro-Psycho Meeting, Doorwerth, the Netherlands : “Liver X Receptor
beta in the CNS”. June, 2007.
511.
Beijing Normal University, Beijing, China: “Estrogen receptor  - a new paradigm in
estrogen signaling”. July, 2007.
512.
Third Military Medical University, Chongqing, China: “New aspects in estrogen signaling”.
July, 2007.
513.
27th International Epilepsy Congress, Singapore: “Estrogens and depression”. July,
2007.
514.
Genome Institute of Singapore: “Biology of estrogen receptor ”. July, 2007.
515.
21st Annual Therapeutic Options for Menopausal Health Conference, Pasadena, USA:
“The role of estrogen signaling in the metabolic syndrome”. July, 2007.
516.
Eli Lilly, Indianapolis, USA: “Estrogen Receptors and the Metabolic Syndrome”. July,
2007.
517.
Tufts-New England Medical Center, Boston, USA: “Update on Estrogen Receptor Beta
Signaling”. July, 2007.
518.
University of Cincinatti, Cincinatti, USA: “An Update on Estrogen Signaling”. July, 2007.
519.
Women’s Mental Health Symposium: A New University of Miami Initative, University of
Miami, Miami, USA: “Targeting estrogen receptor beta offers new pharmaceutical
opportunities – basic and applied aspects”. August, 2007.
47
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
520.
Spetses Summer School on Nuclear Receptor Signalling: From Molecular Mechanisms
to Integrative Physiology, Island of Spetses, Greece: “An update of ER signaling” and
LXR signalling in the central nervous system”.
521.
The Royal Swedish Academy of Sciences: Remedies from animals and plants,
Stockholm, Sweden: “Medical benefit from biologically active compounds in foods.
Phytosteroids”. September, 2007.
522.
Charité – Universitätsmedizin Berlin, Center for Cardiovascular Research, Berlin,
Germany: “Novel paradigms in estrogen signaling”. September, 2007.
523.
Biomedicum Helsinki Seminar Series, Helsinki, Finland: “New paradigms in estrogen
action give new pharmaceutical opportunities for women’s health”. October, 2007.
524.
Brystkreft i fokus, Oslo, Norway: ”Estrogen receptor beta is antiproliferative in breast
cancer”. October, 2007.
525.
The Methodist Hospital Research Institute, Houston, Texas: Inaugural Diabetes and
Metabolic Disease Guest Lecture: “A new paradigm for signal transduction: Estrogen
receptor beta signaling”. October, 2007.
526.
The thirty-eighth International Symposium of The Princess Takamatsu Cancer Research
Fund, Tokyo, Japan, Current challenges in the understanding and management of colon
cancer: “Estrogen receptor  and colon cancer”. November, 2007.
527.
Saitama Medical University, Tokyo, Japan: “LXR and the CNS – possible connections to
the ALS-Parkinsonism dementia complex?”. November, 2007.
528.
Menopause, andropause, anti-aging 2007, Vienna, Austria: “The different impact of
various estrogenic receptors”. December, 2007.
529.
Milan University, Milan, Italy: “Gender differences in targeting nuclear receptor
signalling”. January, 2008.
530.
Serono Symposia International Foundation, “Gene, environment, lifestyle interaction and
human reproduciton, Malmö, Sweden: Keynote lecture: “Effects of perturbed estrogen
signaling on reproductive function”, February, 2008.
531.
Speaker at the Opening Seminar: Sweden – The Best Health Care System in the
World?, Health Care Innovation Week, Swedish Health Care – Research and Innovation,
Washington DC, USA. February, 2008.
532.
Novel Targeted Cancer Therapies: from Cells and Mice to Patients: “Estrogen receptor
beta – a potential new target for treatment of breast and prostate cancer”. Stockholm,
Sweden, March, 2008.
533.
The 3rd Sino-Swedish Cancer Workshop, Guangzhou and Hainan, China, “Estrogen
receptors”. March, 2008.
534.
China-Sweden Workshop on Cancer Treatment and Research, Tianjin, China, “Antiproliferative action of estrogen receptor beta”. March, 2008.
535.
Beijing Normal University, Beijing, China, “The new biology of estrogen signaling”.
March, 2008.
536.
55th Annual Meeting of the Society for Gynecologic Investigation, San Diego, USA,
“Estrogen Receptor-Beta and Reproduction”. Keynote lecture, March, 2008.
48
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
537.
55th Annual Meeting of the Society for Gynecologic Investigation, San Diego, USA,
Debate “Importance of membrane steroid receptors”. For: Carol Lange, Ph.D., Univ. of
Minnesota, Minneapolis, MN, USA. Against: Jan-Åke Gustafsson, M.D., Ph.D. March,
2008.
538.
The LAM Foundation/NHLBI Lymphangioleiomyomatosis, Int. Research Conference,
Cincinnati, USA, “Antiproliferative actions of estrogen receptor beta – possible
implications for LAM”. April, 2008.
539.
11th Frontiers in Nuclear Receptor Action, Savannah, Atlanta, USA, Chairman. April,
2008.
540.
7th Annual Symposium on the Environment and Hormones, e.hormone 2008, New
Orleans, USA, “New Developments in Biology and Mechanisms of Action of ERbeta”.
April, 2008.
541.
Diabetes Research Center, Free University Brussels, Brussels, Belgium, “Estrogen
signaling and the metabolic syndrome”. May, 2008.
542.
Workshop on Pre-receptor steroid metabolism as target for pharmaceutical treatment,
Eibsee, München, Germany, “Nuclear receptors as drug targets in metabolic diseases”.
May, 2008.
543.
XVI Symposium of the International Association on Gnotobiology – Joint with the XXXI
Congress of the Society of Microbial Ecology and Disease, Djurönäset, Stockholm,
Sweden: “Cancer and steroid receptors – state of the art”. May, 2008.
544.
33rd FEBS Congress & 11th IUBMB Conference, Biochemistry of Cell Regulation, Athens,
Greece: “New developments in biology and mechanisms of action of ERbeta”. June/July,
2008.
545.
Estrogen Receptor-beta – Benign Prostatic Hyperplasia, Washington, USA: “ER-beta
biology – Role in Genito-urinary and reproductive systems in men”. July, 2008.
546.
7th Joint Meeting of AFERP, ASP, GA, PSE & SIF, Natural products with pharmaceutical
nutraceutical, cosmetic and agrochemical interest, Athens, Greece: “Plant derived
ligands of nuclear receptors and their biological effects”. August, 2008.
547.
Murikka Minisymposium 2008, Cell signaling and its transcriptional readout, Murikka,
Finland: “New biology of estrogen action”. August, 2008.
548.
Nobel Conference on “Recent advances in understanding estrogen signaling: From
molecular insights to clinical implications”, Sånga-Säby, Stockholm, Sweden: “The new
biology of estrogen signaling”. September, 2008.
549.
The 3rd International Congress of Gender Medicine, Stockholm, Sweden: “Estrogen
signaling in the lung” and “HRT and depression”. September, 2008.
550.
University of Houston, Houston, USA: “Antiproliferative actions of estrogen receptor
beta”. September, 2008.
551.
13th International Congress on Hormonal Steroids and Hormones & Cancer, Quebec,
Canada: “Interplay between ER and ER in estrogen signaling”. September, 2008.
552.
The Thirty-ninth International Symposium of The Princess Takamatsu Cancer Research
Fund, Metabolic Syndrome: Carcinogenesis and Prevention, Tokyo, Japan: “The tumor
49
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
suppressor activity of estrogen receptor beta-implications for cancer prevention”.
November, 2008.
553.
National Cancer Center Research Institute, Tokyo, Japan: “New concepts in estrogen
signaling”. November, 2008.
554.
Round Table Meeting of the Senate Commission on Food Safety of the German
Research Foundation (DFG), Phytoestrogens in food supplements and dietary foods for
special medical purposes, Bonn, Germany: “Estrogen-Receptors: A short overview”.
November, 2008.
555.
Symposium on Sex Steroids, Gothenburg, Sweden: “Estrogen receptors”. November,
2008.
556.
First Serbian Congress of Endocrinology, Belgrade, Serbia: Plenary lecture, “Estrogen
receptor beta as a potential target in the treatment of prostatic cancer”. December, 2008.
557.
Menopause, Andropause, Anti-Aging, Vienna, Austria, “Estrogen receptor beta as a
potential target in treating aging males and females”. December, 2008.
BIBLIOGRAPHY:
Has over 1300 peer-reviewed publications. Can be sent upon request. The list below is selected.
1.
J.-Å. Gustafsson and J. Sjövall: Steroids in germfree and conventional rats. VI.
Identification of 15- and 21-hydroxylated C21 steroids in faeces from germfree rats. Eur.
J. Biochem. 6, 236-247, 1968.
2.
J.-Å. Gustafsson, R. Ryhage, J. Sjövall and R.M. Moriarty: Migrations of the trimethylsilyl
group upon electron impact in steroids. J. Am. Chem. Soc. 91, 1234-1236, 1969.
3.
P. Eneroth and J.-Å. Gustafsson: Steroids in newborns and infants. Identification of
20,22-dihydroxycholesterol from the monosulphate and "disulphate" fractions in human
meconium. FEBS Lett. 5, 99-103, 1969.
4.
I. Björkhem and J.-Å. Gustafsson: Mechanism of microbial transformation of cholesterol
into coprostanol. Eur. J. Biochem. 21 428-432, 1971.
5.
K. Einarsson, J.-Å. Gustafsson and Å. Stenberg: Neonatal imprinting of liver microsomal
hydroxylation and reduction of steroids. J. Biol. Chem. 248, 4987-4997, 1973.
6.
A. Berg and J.-Å. Gustafsson: Regulation of hydroxylation of 5-androstane-3, 17-diol
in liver microsomes from male and female rats. J. Biol. Chem. 248, 6559-6567, 1973.
7.
J.-Å. Gustafsson and Å. Stenberg: Irreversible androgenic programming at birth of
microsomal and soluble liver enzymes active on 4-androstene-3,17-dione and 5androstane-3,17 -diol. J. Biol. Chem. 249, 711-718, 1974.
8.
J.-Å. Gustafsson and Å. Stenberg: Neonatal programming of androgen responsiveness
of liver of adult rats. J. Biol. Chem. 249, 719-723, 1974.
50
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
9.
J.-Å. Gustafsson and M. Ingelman-Sundberg: Regulation and properties of a sex-specific
hydroxylase system in female rat liver microsomes active on steroid sulphates. I. General
characteristics. J. Biol. Chem. 249, 1940-1945, 1974.
10.
J.-Å. Gustafsson and Å. Stenberg: Masculinization of rat liver enzyme activities following
hypophysectomy. Endocrinology 95, 891-896, 1974.
11.
J.-Å. Gustafsson and M. Ingelman-Sundberg: Regulation and substrate specificity of a
steroid sulfate-specific hydroxylase system in female rat liver microsomes. J. Biol. Chem.
250, 3451-3458, 1975.
12.
J.-Å. Gustafsson and Å. Pousette: Demonstration and partial characterization of cytosol
receptors for testosterone. Biochemistry 14, 3094-3101, 1975.
13.
J.-Å. Gustafsson, A. Larsson, P. Skett and Å. Stenberg: Influence of a novel hypophyseal
factor on steroid metabolism in cultured hepatoma cells. Proc. Natl. Acad. Sci. USA 72,
4986-4990, 1975.
14.
B.E. Gustafsson, K. Einarsson and J.-Å. Gustafsson: Influence of cholesterol feeding on
liver microsomal metabolism of steroids and bile acids in conventional and germ-free rats.
J. Biol. Chem. 250, 8496-8502, 1975.
15.
J.-Å. Gustafsson and Å. Stenberg: Partial masculinization of rat liver enzyme activities
following treatment with FSH. Endocrinology 96, 501-504, 1975.
16.
A. Berg, J.-Å. Gustafsson, M. Ingelman-Sundberg and K. Carlström: Characterization of
a cytochrome P-450-dependent steroid hydroxylase system present in Bacillus
megaterium. J. Biol. Chem. 251, 2831-2838, 1976.
17.
J.-Å. Gustafsson and Å. Stenberg: On the obligatory role of the hypophysis in sexual
differentiation of hepatic metabolism in rats. Proc. Natl. Acad. Sci. USA 73, 1462-1465,
1976.
18.
P. Eneroth, J.-Å. Gustafsson, A. Larsson, P. Skett and Å. Stenberg: Feminization of
hepatic steroid metabolism in male rats with a transplanted pituitary tumor (MtT/F4). Cell
7, 413-417, 1976.
19.
J.-Å. Gustafsson, M. Ingelman-Sundberg, Å. Stenberg and T. Hökfelt: Feminization of
hepatic steroid metabolism in male rats following electrothermic lesion of the
hypothalamus. Endocrinology 98, 922-926, 1976.
20.
J.-Å. Gustafsson and Å. Stenberg: Specificity of neonatal, androgen-induced imprinting of
hepatic steroid metabolism in rats. Science 191, 203-204, 1976.
21.
J.-Å. Gustafsson, Å. Pousette and E. Svensson: Sex-specific occurrence of androgen
receptors in rat brain. J. Biol. Chem. 251, 4047-4054, 1976.
22.
P. Skett, P. Eneroth, J.-Å. Gustafsson and C. Sonnenschein: Changes in hepatic steroid
metabolism in rats following transplantation of four different clones of pituitary tumor cells.
Endocrinology 100, 1090-1096, 1977.
51
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
23.
K. Fuxe, T. Hökfelt, P. Eneroth, J.-Å. Gustafsson and P. Skett: Prolactin-like
immunoreactivity: localization in nerve terminals of rat hypothalamus. Science 196, 899900, 1977.
24.
M. Snochowski, Å. Pousette, P. Ekman, D. Bression, L. Andersson, B. Högberg and J.-Å.
Gustafsson: Characterization and measurement of the androgen receptor in human
benign prostatic hyperplasia and prostatic carcinoma. J. Clin. Endocrinol. Metab. 45, 920930, 1977.
25.
Ö. Wrange and J.-Å. Gustafsson: Separation of the hormone- and DNA-binding sites of
the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253, 856-865,
1978.
26.
Ö. Wrange, B. Nordenskjöld and J.-Å. Gustafsson: Cytosol estradiol receptor in human
mammary carcinoma: An assay based on isoelectric focusing in polyacrylamide gel. Anal.
Biochem. 85, 461-475, 1978.
27.
J.-Å. Gustafsson, P. Eneroth, T. Hökfelt and P. Skett: Central control of hepatic steroid
metabolism: effect of discrete hypothalamic lesions. Endocrinology 103, 141-151, 1978.
28.
Ö. Wrange, J. Carlstedt-Duke and J.-Å. Gustafsson: Purification of the glucocorticoid
receptor from rat liver cytosol. J. Biol. Chem. 254, 9284-9290, 1979.
29.
A. Berg, M. Ingelman-Sundberg and J.-Å. Gustafsson: Purification and characterization
of cytochrome P-450meg. J. Biol. Chem. 254, 5264-5271, 1979.
30.
J. Carlstedt-Duke, Ö. Wrange, E. Dahlberg, J.-Å. Gustafsson and B. Högberg:
Transformation of the glucocorticoid receptor in rat liver cytosol by lysosomal enzymes. J.
Biol. Chem. 254, 1537-1539, 1979.
31.
Ö. Wrange, J. Carlstedt-Duke and J.-Å. Gustafsson: Purification of the glucocorticoid
receptor from rat liver cytosol. J. Biol. Chem. 254, 9284-9290, 1979.
32.
B. Forsgren, P. Björk, K. Carlström, J.-Å. Gustafsson, Å. Pousette and B. Högberg:
Purification and distribution of a major protein in rat prostate that binds estramustine, a
nitrogen mustard derivative of estradiol-17. Proc. Natl. Acad. Sci. USA 76, 3149-3153,
1979.
33.
J.-Å. Gustafsson, Å. Pousette and Ö. Wrange: Predictive tests in treatment of breast and
prostatic carcinoma based on steroid receptor assays. Trends Pharmacol. Sci., pp. 279281, June, 1980.
34.
J.E. Bakke, J.-Å. Gustafsson and B.E. Gustafsson: Metabolism of propachlor by the
germfree rat. Science 210, 433-435, 1980.
35.
S. Okret, J. Carlstedt-Duke, Ö. Wrange, K. Carlström and J.-Å. Gustafsson:
Characterization of an antiserum against the glucocorticoid receptor. Biochem. Biophys.
Acta 667, 205-219, 1981.
52
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
36.
A. Mode, G. Norstedt, B. Simic, P. Eneroth and J.-Å. Gustafsson: Continuous infusion of
growth hormone feminizes hepatic steroid metabolism in the rat. Endocrinology 108, 21032108, 1981.
37.
F. Payvar, Ö. Wrange, J. Carlstedt-Duke, S. Okret, J.-Å. Gustafsson and K.R.
Yamamoto: Purified glucocorticoid receptors bind selectively in vitro to a cloned DNA
fragment whose transcription is regulated by glucocorticoids in vivo. Proc. Natl. Acad. Sci.
USA 78, 6628-6632, 1981.
38.
J. Carlstedt-Duke, S. Okret, Ö. Wrange and J.-Å. Gustafsson: Immunochemical analysis
of the glucocorticoid receptor: identification of a third domain separate from the steroidbinding and DNA-binding domains. Proc. Natl. Acad. Sci. USA 79, 4260-4264, 1982.
39.
A. Mode, J.-Å. Gustafsson, J.-O. Jansson, S. Edén and O. Isaksson: Association
between plasma level of growth hormone and sex differentiation of hepatic steroid
metabolism in the rat. Endocrinology 111, 1692-1697, 1982.
40.
G. Norstedt, A. Mode, T. Hökfelt, P. Eneroth, R. Elde, L. Ferland, F. Labrie and J.-Å.
Gustafsson: Possible role of somatostatin in the regulation of the sexually differentiated
steroid metabolism and prolactin receptor in rat liver. Endocrinology 112, 1076-1090,
1983.
41.
A. Mode, G. Norstedt, P. Eneroth and J.-Å. Gustafsson: Purification of liver feminizing
factor from rat pituitaries and demonstration of its identity with growth hormone.
Endocrinology 113, 1250-1260, 1983.
42.
F. Payvar D. DeFranco, G.L. Firestone, B. Edgar, Ö. Wrange, S Okret, J.-Å. Gustafsson
and K.R. Yamamoto: Sequence-specific binding of glucocorticoid receptor to MTV DNA at
sites within and upstream of the transcribed region. Cell 35, 381-392, 1983.
43.
J.-Å. Gustafsson, A. Mode and G. Norstedt: Central control of prolactin and estrogen
receptors in rat liver - expression of a novel endocrine system, the hypothalamo-pituitaryliver axis. Ann. Rev. Pharmacol. Toxicol. 23, 259-278, 1983.
44.
J.-Å. Gustafsson, A. Mode, G. Norstedt and P. Skett: Sex steroid induced changes in
hepatic enzymes. Ann. Rev. Physiol. 45, 51-60, 1983.
45.
L. Haglund, C. Köhler, T. Haaparanta, M. Goldstein and J.-Å. Gustafsson: Presence of
NADPH-cytochrome P-450 reductase in central catecholaminergic neurones. Nature 307,
259-262, 1984.
46.
S. Okret, A.-C. Wikström, Ö. Wrange, B. Andersson and J.-Å. Gustafsson:
Monoclonal antibodies against the rat liver glucocorticoid receptor. Proc. Natl. Acad. Sci.
USA 81, 1609-1613, 1984.
47.
Ö. Wrange, S. Okret, M. Radojcic, J. Carlstedt-Duke and J.-Å. Gustafsson:
Characterization of the purified activated glucocorticoid receptor from rat liver cytosol. J.
Biol. Chem. 259, 4534-4541, 1984.
53
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
48.
R. Miesfeld, S. Okret, A.-C. Wikström, Ö. Wrange, J.-Å. Gustafsson and K. Yamamoto:
Characterization of a steroid receptor gene and mRNA in wild-type and mutant cells.
Nature 312, 779-781, 1984.
49.
J. Bakke, C. Struble, J.-Å. Gustafsson and B. Gustafsson: Catabolism of premercapturic
acid pathway metabolites of naphthlene to naphthols and methylthio-containing
metabolites in rats. Proc. Natl. Acad. Sci. USA 82, 668-671, 1985.
50.
J. Lund, I. Brandt, L. Poellinger, Å. Bergman, E. Klasson-Wehler and J.-Å. Gustafsson:
Target cells for the polychlorinated biphenyl metabolite 4,4'-bis(methylsulfonyl)-2,2',5,5'tetrachlorobiphenyl. Characterization of high affinity binding in rat and mouse lung cytosol.
Mol. Pharmacol. 27, 314-323, 1985.
51.
M. Gillner, J. Bergman, C. Cambillau, B. Fernström and J.-Å. Gustafsson: Interactions of
indoles with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol.
Pharmacol. 28, 357-363, 1985.
52.
J.-O. Jansson, S. Ekberg, O. Isaksson, A. Mode and J.-Å. Gustafsson: Imprinting of
growth hormone secretion, body growth, and hepatic steroid metabolism by neonatal
testosterone. Endocrinology 117, 1881-1889, 1985.
53.
K. Fuxe, A.-C. Wikström, S. Okret, L.F. Agnati, A. Härfstrand, Z.-Y. Yu, L. Granholm, M.
Zoli, W. Vale and J.-Å. Gustafsson: Mapping of glucocorticoid receptor immunoreactive
neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver
glucocorticoid receptor. Endocrinology 117, 1803-1812, 1985.
54.
S. Okret, L. Poellinger, Y. Dong and J.-Å. Gustafsson: Down-regulation of glucocorticoid
receptor mRNA by glucocorticoid hormones and recognition by the receptor of a specific
binding sequence within a receptor cDNA clone. Proc. Natl. Acad.Sci. USA 83, 5899-5903,
1986.
55.
R. Miesfield, S. Rusconi, P.J. Godowski, B.A. Maler, S. Okret, A.-C. Wikström, J.-Å.
Gustafsson and K.R. Yamamoto: Genetic complementation of a glucocorticoid receptor
deficiency by expression of cloned receptor cDNA. Cell 46, 389-399, 1986.
56.
Ö. Wrange, J. Carlstedt-Duke and J.-Å. Gustafsson: Stoichiometric analysis of the
specific interaction of the glucocorticoid receptor with DNA. J. Biol. Chem. 261, 1177011778, 1986.
57.
J. Carlstedt-Duke, P.-E. Strömstedt, Ö. Wrange, T. Bergman, J.-Å. Gustafsson:
Domain structure of the glucocorticoid receptor protein. Proc. Natl. Acad. Sci. USA 84,
4437-4440, 1987.
58.
M. Denis, A.-C. Wikström and J.-Å. Gustafsson: The molybdate-stabilized non-activated
glucocorticoid receptor contains a dimer of Mr 90,000 non-hormone-binding protein. J.
Biol. Chem. 262, 11803-11806, 1987.
59.
J.-Å. Gustafsson, J. Carlstedt-Duke, L. Poellinger, S. Okret, A.-C. Wikström, M.
Brönnegård, M. Gillner, Y. Dong, K. Fuxe, A. Cintra, A. Härfstrand and L. Agnati:
Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocrine
Reviews 8, 185-234, 1987.
54
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
60.
A. Hecht, A. Berkenstam, P.-E. Strömstedt, J.-Å. Gustafsson and A.E. Sippel: A
progesterone responsive element maps to the far upstream steroid dependent DNase
hypersensitive site of chicken lysozyme chromatin. EMBO J. 7, 2063-2073, 1988.
61.
P.G. Zaphiropoulos, A. Mode, A. Ström, C. Möller, C. Fernandez and J.-Å. Gustafsson:
cDNA cloning, sequence, and regulation of a major female-specific and growth hormoneinducible rat liver cytochrome P-450 active in 15-hydroxylation of steroid sulfates. Proc.
Natl. Acad. Sci. USA 85, 4214-4217, 1988.
62.
D.D. Sakai, S. Helms, J. Carlstedt-Duke, J.-Å. Gustafsson, F.M. Rottman and K.R.
Yamamoto: Hormone-mediated repression: a negative glucocorticoid response element
from the bovine prolactin gene. Genes & Development 2, 1144-1154, 1988.
63.
J. Carlstedt-Duke, P.-E. Strömstedt, B. Persson, E. Cederlund, J.-Å. Gustafsson and H.
Jörnvall: Identification of hormone-interacting amino acid residues within the steroidbinding domain of the glucocorticoid receptor in relation to other steroid hormone
receptors. J. Biol. Chem. 263, 6843-6846, 1988.
64.
M. Denis, L. Poellinger, A.-C. Wikström and J.-Å. Gustafsson: Requirement of hormone
for thermal conversion of the glucocorticoid receptor to a DNA-binding state. Nature 33,
686-688, 1988.
65.
S.Y. Tsai, J. Carlstedt-Duke, N.L. Weigel, K. Dahlman, J.-Å. Gustafsson, M.-J. Tsai and
B.W. O'Malley: Molecular interactions of steroid hormone receptor with its enhancer
element: evidence for receptor dimer formation. Cell 55, 361-369, 1988.
66.
P.S. Guzelian, D. Li, E.G. Schuetz, P. Thomas, W. Levin, A. Mode and J.-Å. Gustafsson:
Sex change in cytochrome P-450 phenotype by growth hormone treatment of adult rat
hepatocytes maintained in a culture system on matrigel. Proc. Natl. Acad. Sci. USA 85,
9783-9787, 1988.
67.
M. Aronsson, K. Fuxe, Y. Dong, L.F. Agnati, S. Okret and J.-Å. Gustafsson: Localization
of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proc. Natl.
Acad. Sci. USA 85, 9331-9335, 1988.
68.
P.G. Zaphiropoulos, A. Mode, G. Norstedt and J.-Å. Gustafsson: Regulation of sexual
differentiation in drug and steroid metabolism. Trends Pharmacol. Sci., 10, 149-153, 1989.
69.
K. Dahlman, P.-E. Strömstedt, C. Rae, H. Jörnvall, J.-I. Flock, J. Carlstedt-Duke and J.-Å.
Gustafsson: High level expression in Escherichia coli of the DNA-binding domain of the
glucocorticoid receptor in a functional form utilizing domain-specific cleavage of a fusion
protein. J. Biol. Chem. 264, 804-809, 1989
70.
M. Warner, M. Strömstedt, L. Möller and J.-Å. Gustafsson: Distribution and regulation of
5-androstane-3,17-diol hydroxylase in the rat central nervous system. Endocrinology
124, 1246-2699, 1989.
71.
Y. Dong, M. Aronsson, J.-Å. Gustafsson and S. Okret: The mechanism of cAMP-induced
glucocorticoid receptor expression. Correlation to cellular glucocorticoid response. J. Biol.
Chem. 23, 13679-13686, 1989.
55
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
72.
A. Mode, E. Wiersma-Larsson and J.-Å. Gustafsson: Transcriptional and
posttranscriptional regulation of sexually differentiated rat liver cytochrome P-450 by
growth hormone. Mol. Endocrinol. 3, 1142-1147, 1989.
73.
P.G. Zaphiropoulos, A. Ström, J.A. Robertson and J.-Å. Gustafsson: Structural and
regulatory analysis of the male-specific rat liver cytochrome P-450g: Repression by
continuous growth hormone administration. Mol. Endocrinol. 4, 53-58, 1990.
74.
L. Nordlund-Möller, O. Andersson, R. Ahlgren, J. Schilling, M. Gillner, J.-Å. Gustafsson
and J. Lund: Cloning, structure, and expression of a rat binding protein for polychlorinated
biphenyls. J. Biol. Chem., 265, 12690-12693, 1990.
75.
E. Imai, P.-E. Strömstedt, P. G. Quinn, J. Carlstedt-Duke, J.-Å. Gustafsson and D. K.
Granner: Characterization of a complex glucocorticoid response unit in the
phosphoenolpyruvate carboxykinase gene. Mol.Cell. Biol., 10, 4712-4719, 1990.
76.
T. Härd, E. Kellenbach, R. Boelens, B. A. Maler, K. Dahlman, L. P. Freedman, J.
Carlstedt-Duke, K. R. Yamamoto, J.-Å. Gustafsson, and R. Kaptein: Solution structure of
the glucocorticoid receptor DNA-binding domain. Science, 249, 157-160, 1990.
77.
P.-E. Strömstedt, L. Poellinger, J.-Å. Gustafsson, and J. Carlstedt-Duke: The
Glucocorticoid Receptor Binds to a Sequence Overlapping the TATA Box of the Human
Osteocalcin Promoter: a Potential Mechanism for Negative Regulation. Mol. Cell. Biol, 11,
3379-3383, 1991.
78.
A.P.H. Wright, I.J. McEwan, K. Dahlman-Wright, and J.-Å. Gustafsson: High level
expression of the major transactivation domain of the human glucocorticoid receptor in
yeast cells inhibits endogenous gene expression and cell growth. Mol. Endocrinology.,5,
1366-1372, 1991.
79.
M. Göttlicher, E. Widmark, Q. Li, and J.-Å. Gustafsson: Fatty acids activate a chimera of
the clofibric acid-activated receptor and the glucocorticoid receptor. Proc.Natl.Acad.Sci.
USA, 89, 4653-4657, 1992.
80.
M. Rudling, G. Norstedt, H. Olivecrona, E. Reihnér, J.-Å. Gustafsson and B. Angelin:
Importance of growth hormone for the induction of hepatic low density lipoprotein
receptors. Proc.Natl.Acad.Sci. USA, 89, 6983-6987, 1992.
81.
L. Poellinger, M. Göttlicher and J.-Å. Gustafsson: The dioxin and peroxisome proliferatoractivated receptors: nuclear receptors in search of endogenous ligands. Trends
Pharmacol. Sci., 13, 241-245, 1992.
82.
I.J. McEwan, A.P.H. Wright, K. Dahlman-Wright, J. Carlstedt-Duke, and J.-Å. Gustafsson:
Direct interaction of the 1 transactivation domain of the human glucocorticoid receptor
with the basal transcriptional machinery. Mol. Cell. Biol., 13, 399-407, 1993.
83.
K. L. Gearing, M. Göttlicher, M. Teboul, E. Widmark, and J.-Å. Gustafsson: Interaction of
the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad.
Sci. USA, 90, 1440-1444, 1993.
56
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
84.
M. Gillner, J. Bergman, C. Cambillau, M. Alexandersson, B. Fernström, and J.-Å.
Gustafsson: Interactions of indolo[3,2-b]carbazoles and related polycyclic aromatic
hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver.
Mol. Pharmacol., 44, 336-345, 1993.
85.
C.D. Banner, M. Göttlicher, E. Widmark, J. Sjövall, J.J. Rafter, and J.-Å. Gustafsson: A
systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear
receptor from biological extracts: characterization of peroxisome proliferator-activated
receptor activators in plasma. J. Lipid Res., 34, 1583-1591, 1993.
86.
T. Härd and J.-Å. Gustafsson: Structure and function of the DNA-binding domain of the
glucocorticoid receptor and other members of the nuclear receptor supergene family.
Accounts of Chem. Res., 26, 644-650, 1993.
87.
M. Warner and J.-Å. Gustafsson: Effect of ethanol on cytochrome P450 in the rat brain.
Proc. Natl. Acad. Sci. USA., 91, 1019-1023, 1994.
88.
K. Dahlman-Wright, T. Almlöf, I.J. McEwan, J.-Å. Gustafsson and A.P.H. Wright:
Delineation of a small region within the major transactivation domain of the human
glucocorticoid receptor that mediates transactivation of gene expression. Proc. Natl. Acad.
Sci. USA. 91, 1619-1623, 1994.
89.
J. Zilliacus, J. Carlstedt-Duke, J.-Å. Gustafsson and A.P.H. Wright: Evolution of distinct
DNA-binding specificities within the nuclear receptor family of transcription factors.
Proc.Natl. Acad. Sci. USA., 91, 4175-4179, 1994.
90.
H. E. Witkowska, C. H. L. Shackleton, K. Dahlman-Wright, J. Y. Kim, and J.-Å.
Gustafsson: Mass spectrometric analysis of a native zinc-finger structure: The
glucocorticoid receptor DNA binding domain. J. Am. Chem. Society, 117, 3319-3324,
1995.
91.
M. Teboul, E. Enmark, Q. Li, A.C. Wikström, M. Pelto-Huikko, and J.-Å. Gustafsson: OR1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid
receptor. Proc. Natl. Acad. Sci. USA, 92, 2096-2100, 1995.
92.
E. Caldenhoven, J. Lidén, S. Wissink, A. Van de Stolpe, J. Raaijmakers, L. Koenderman,
S. Okret, J.-Å. Gustafsson, and P. T. Van der Saag: Negative cross-talk between ReIA
and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of
glucocorticoids. Mol. Endocrinol. 9, 401-412, 1995.
93.
K. Dahlman-Wright, H. Baumann, I. J. McEwan, T. Almlöf, A.P.H. Wright, J.-Å.
Gustafsson, and T. Härd: Structural characterization of a minimal functional
transactivation domain from the human glucocorticoid receptor. Proc.Natl.Acad.Sci. USA,
92, 1699-1703, 1995.
94.
T. Härd, H.J. Barnes, C. Larsson, J.-Å. Gustafsson and J. Lund: Solution structure of a
mammalian PCB-binding protein in complex with a PCB. Nature Struct. Biol.2, 983-989,
1995.
95.
M. Warner and J.-Å. Gustafsson: Cytochrome P450 in the brain: Neuroendocrine
functions. Frontiers in Neuroendocrinology, 16, 224-236, 1995.
57
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
96.
E. Enmark and J.-Å. Gustafsson: Orphan nuclear receptor - The first eight years. Mol.
Endocrinol. 10, 1293-1307, 1996.
97.
G.G.J.M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-Å. Gustafsson: Cloning
of a novel estrogen receptor expressed in rat prostate and ovary. Proc.Natl.Acad.Sci. USA
93, 5925-5930, 1996.
98.
G. Spyrou, E. Enmark, A. Miranda-Vizuete, and J.-Å. Gustafsson: Cloning and
expression of a novel mammalian thioredoxin. J. Biol. Chem., 272, 2936-2941, 1997.
99.
T. Almlöf, J.-Å. Gustafsson, and A.P.H. Wright: Role of hydrophobic amino acid clusters
in the transactivation activity of the human glucocorticoid receptor. Mol. Cell Biol., 17, 934945, 1997.
100. M. Byers, G.G.J.M. Kuiper, J.-Å. Gustafsson, and O.-K. Park-Sarge: Estrogen receptor-
mRNA expression in rat ovary: Down-regulation by gonadotropins. Mol. Endocrinol. 11,
172-182, 1997.
101. A. Henriksson, T. Almlöf, J. Ford, I.J. McEwan, J.-Å. Gustafsson and A.P.H. Wright: Role
of the Ada Adaptor Complex in Gene Activation by the Glucocorticoid Receptor. Mol. Cell
Biol. 3065-3073, 1997.
102. K. Pettersson, K. Grandien, G. G. J. M. Kuiper and J.-Å. Gustafsson: Mouse estrogen
receptor  forms estrogen response element binding heterodimers with estrogen receptor
. Mol. Endocrinol. 11, 1486-1496, 1997.
103. K. Paech, P. Webb, G. G.J.M. Kuiper, S. Nilsson, J.-Å. Gustafsson, P. J.Kushner, and T.
S. Scanlan: Differential transactivation properties of the estrogen receptor isotypes (, ):
Estrogen-like effects with antiestrogens and antiestrogen effects with estrogen. Science,
277, 1508-1510, 1997.
104. A.M. Brzozowski, A.C.W. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engström, L.
Öhman, G.L. Greene, J.-Å. Gustafsson and M. Carlquist: Insights into the molecular
basis of agonism and antagonism in the oestrogen receptor as revealed by complexes
with 17-oestradiol and raloxifene. Nature, 389, 753-758, 1997.
105. F.F. Wiebel, J.-Å. Gustafsson: Heterodimeric interaction between RXR and orphan
nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of
nuclear receptor activation. Mol. Cell. Biol., 17, 3977-3986, 1997.
106. F. Delaunay, A. Khan, A. Cintra, B. Davani, Z.-C. Ling, A. Andersson, C.-G. Östenson, J.Å. Gustafsson, S. Efendic, and S. Okret: Pancreatic -cells are important targets for the
diabetogenic effects of glucocorticoids. J. Clin. Invest. 100, 2094-2098, 1997.
107. E. Enmark, M. Pelto-Huikko, K. Grandien, S. Lagercrantz, J. Lagercrantz, G. Fried, M.
Nordenskjöld and J.-Å. Gustafsson: Human estrogen receptor -gene structure,
chromosomal localization and expression pattern. J. Clin. Endocrinol. Metab., 82, 42584265, 1997.
58
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
108. J.-Å. Gustafsson: Estrogen receptor - Getting in on the action? Nature Medicine, 3,
493-494, 1997.
109. E. Treuter, T. Albrektsen, L. Johansson, J. Leers, and J.-Å. Gustafsson: A regulatory role
for RIP140 in nuclear receptor activation. Mol. Endocrinol., 12, 864-881, 1998.
110. G.G.J.M. Kuiper, J.G. Lemmen, B. Carlsson, J.C. Corton, S.H. Safe, P. T. van der Saag,
B. van der Burg, and J.-Å. Gustafsson: Interaction of estrogenic chemicals and
phytoestrogens with estrogen receptor . Endocrinology, 139, 4252-4263, 1998.
111. J. H. Krege, J. B. Hodgin, J. F. Couse, E. Enmark, M. Warner, J. F. Mahler, M. Sar, K. S.
Korach, J.-Å. Gustafsson, and O. Smithies: Generation and reproductive phenotypes of
mice lacking estrogen receptor . Proc.Natl.Acad.Sci. USA, 95, 15677-15682, 1998.
112. G.G.J.M. Kuiper, P.J. Shughrue, M. Pelto-Huikko, I. Merchenthaler and J.-Å. Gustafsson:
The estrogen receptor  subtype: A novel mediator of estrogen action in neuroendocrine
systems. Frontiers in Neuroendocrinol, 19, 253-286, 1998.
113. J.-Å. Gustafsson: Raloxifene: Magic bullet for heart and bone? Nature Medicine, 4, 152,
1998.
114. S. Nilsson, G. Kuiper and J.-Å. Gustafsson: ER: a novel estrogen receptor offers the
potential for new drug development. Trends Endocrin. Met., 9, 387-395, 1998.
115. J.-Å. Gustafsson: Therapeutic potential of selective estrogen receptor modulators.
Current Opinion in Chemical Biology, 2, 508-511, 1998.
116. G.G.J.M. Kuiper, M. Carlquist, and J.-Å. Gustafsson: Estrogen is a male and female
hormone. Science & Medicine, 5, 36-45, 1998.
117. A.Dumont, S.P. Hehner, M.L. Schimtz, J.-Å. Gustafsson, J. Lidén, S. Okret, P. T. van der
Saag, S. Wissink, B. van der Burg, P. Herrlich, G. Haegeman, K. de Bosscher and W.
Fiers: Cross-talk between steroids and NF-B: what language? Trends Biochem. Sci.,
233-235, 1998.
118. Johansson, J. S. Thomsen, A. E. Damdimopoulos, G. Spyrou, J.-Å. Gustafsson, and E.
Treuter: The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional
activity of estrogen receptors ER and ER. J. Biol. Chem., 247, 345-353, 1999.
119. E. Treuter, L. Johansson, J.S. Thomsen, A. Wärnmark, J. Leers, M. Pelto-Huikko, M.
Sjöberg, A.P.H. Wright, G. Spyrou, and J.-Å. Gustafsson: Competition between thyroid
hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor
(TIF) 2 for binding to nuclear receptors. J. Biol. Chem., 274, 6667-6677, 1999.
120. S. Mäkelä, H. Savolainen, E. Aavik, M. Myllärniemi, L. Strauss, E. Taskinen, J.-Å.
Gustafsson, and P. Häyry: Differentiation between vasculoprotective and uterotrophic
effects of ligands with different binding affinities to estrogen receptors and . Proc. Natl.
Acad. Sci. USA, 96, 7077-7082, 1999.
59
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
121. J.-M. Vanacker, K. Pettersson, J.-Å. Gustafsson and V. Laudet: Transcriptional targets
shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) , but
not by ER. EMBO J. 18, 4270-4279, 1999.
122. A.C.W. Pike, A.M. Brzozowski, R.E. Hubbard, T. Bonn, A.-G. Thorsell, O. Engström, J.
Ljunggren, J.-Å. Gustafsson and M. Carlquist: Structure of the ligand-binding domain of
oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO
J., 18, 4608-4618, 1999.
123. S. Ogawa, J. Chan, A.E. Chester, J.-Å. Gustafsson, K.S. Korach, and D.W. Pfaff:
Survival of reproductive behaviors in estrogen receptor  gene-deficient (ERKO) male
and female mice. Proc.Natl.Acad.Sci.USA, 96, 12887-12892, 1999.
124. S.H Windahl, O. Vidal, G. Andersson, J.-Å. Gustafsson, and C. Ohlsson: Increased
cortical bone mineral content but unchanged trabecular bone mineral density in female
ER -/- mice. J. Clin. Invest., 104, 895-901, 1999.
125. J.-Å. Gustafsson: Seeking ligands for lonely orphan receptors. Science, 284, 1285-1286,
1999.
126. L.D. Croce, S. Okret, S. Kersten, J.-Å. Gustafsson, M. Parker, W. Wahli and M. Beato:
Steroid and nuclear receptors. EMBO J., 18, 6201-6210, 1999.
127. S. Saji, E. V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J.-Å. Gustafsson:
Estrogen receptors  and  in the rodent mammary gland. Proc.Natl.Acad.Sci. USA, 97,
337-342, 2000.
128. F. Caira, P. Antonson, M. Pelto-Huikko, E. Treuter, and J.-Å. Gustafsson: Cloning and
characterization of RAP250, a novel nuclear receptor coactivator. J. Biol. Chem. 275,
5308-5317, 2000.
129. C. Patrone, G. Pollio, E. Vegeto, E. Enmark, I. de Curtis, J.-Å. Gustafsson and A. Maggi:
Estradiol induces differential neuronal phenotypes by activating estrogen receptor  or .
Endocrinol., 141, 1839-1845, 2000.
130. Z. Weihua, S. Saji, S. Mäkinen, G. Cheng, E. V. Jensen, M. Warner and J.-Å.
Gustafsson: Estrogen receptor (ER) ,a modulator of ER in the uterus.
Proc.Natl.Acad.Sci. USA, 97, 5936-5941, 2000.
131. K. Pettersson, F. Dalaunay, and J.-Å. Gustafsson: Estrogen receptor  acts as a
dominant regulator of estrogen signaling. Oncogene, 19, 4970-4978, 2000.
132. C. M. Sadek, S. Jalaguier, E P. Feeney, M. Aitola, A. E. Damdimopoulos, M. Pelto-Huikko,
J.-Å. Gustafsson. Isolation and characterization of AINT: a novel ARNT interacting
protein expressed during murine embryonic development. Mechanisms of Development
97, 13-26, 2000.
133. A. Ström, N. Arai, J. Leers, and J.-Å. Gustafsson. The Hairy and Enhancer of Split
homologue-1 (HES-1) mediates the proliferative effect of 17-estradiol on breast cancer
cell lines. Oncogene, 19, 5951-5953, 2000.
60
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
134. H. Zhang, J. S. Thomsen, L. Johansson, J.-Å. Gustafsson, and E. Treuter. DAX-1
functions as an LXXLL-containing corepressor for activated estrogen receptors. J. Biol.
Chem., 275, 39855-39859, 2000.
135. S. Ogawa, A.E. Chester, S. Curtis Hewitt, V. R. Walker, J.-Å. Gustafsson, O. Smithies,
K.S. Korach, and D. W. Pfaff. Abolition of male sexual behaviors in mice lacking estrogen
receptors  and  (ERKO). Proc.Natl.Acad.Sci. USA, 97, 14737-14741, 2000.
136. C. Palmieri, S. Saji, J.-Å. Gustafsson, R C. Coombes: False negatives in oestrogenreceptor assay. The Lancet, 356, 944, 2000.
137. E. Enmark and J.-Å. Gustafsson: Nematode genome sequence dramatically extends the
nuclear receptor superfamily. Trends Pharmacol. Sci., 21, 85-87, 2000.
138. L. Wang, S. Andersson, M. Warner, and J.-Å. Gustafsson: Morphological abnormalities in
the brains of estrogen receptor  knockout mice. Proc.Natl.Acad.Sci. USA, 98, 2792-2796,
2001.
139. S. Alberti, G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B. Angelin, I.
Björkhem, S. Pettersson, and J.-Å. Gustafsson: Hepatic cholesterol metabolism and
resistance to dietary cholesterol in LXR-deficient mice. J. Clin. Invest., 107, 565-573,
2001.
140. A. C. W. Pike, A. M. Brzozowski, J. Walton, R. E. Hubbard, A.-G. Thorsell, Y.-L. Li, J.-Å.
Gustafsson, and M. Carlquist: Structural insights into the mode of action of a pure
antiestrogen. Structure, 9, 145-153, 2001.
141. Z. Weihua, S. Mäkelä, L. C. Andersson, S. Salmi, S. Saji, J. I. Webster, E. V. Jensen, S.
Nilsson, M. Warner, and J.-Å. Gustafsson: A role for estrogen receptor  in the regulation
of growth of the ventral prostate. Proc.Natl.Acad.Sci. USA, 98, 6330-6335, 2001.
142. K. Rose, A. Allan, S. Gauldie, G. Stapleton, L. Dobbie, K. Dott, C. Martin, L. Wang, E.
Hedlund, J. R. Seckl, J.-Å. Gustafsson, and R. Lathe: Neurosteroid hydroxylase CYP7B
vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread
pathway of steroid and oxysterol hydroxylation. J. Biol. Chem., 276, 23937-23944, 2001.
143. L. G. Horvath, S. M.. Henshall, C.-S. Lee, D. R. Head, D. I. Quinn, S. Makela, W.
Delprado, D. Golovsky, P. C. Brenner, G. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel,
J.-Å. Gustafsson, and R. L. Sutherland: Frequent loss of estrogen receptor- expression
in prostate cancer. Cancer Res., 61, 5331-5335, 2001.
144. S.H. Windahl, K. Hollberg, O. Vidal, J.-Å. Gustafsson, C. Ohlsson, and G. Andersson:
Female estrogen receptor  -/- mice are partially protected against age-related trabecular
bone loss. J. Bone and Mineral Res., 16, 2001.
145. K. Pettersson and J.-Å. Gustafsson: Role of estrogen receptor beta in estrogen action.
Annu. Rev. Physiol., 63, 165-92, 2001.
61
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
146. S. Nilsson, S. Mäkelä, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K.
Pettersson, M. Warner, and J.-Å. Gustafsson: Mechanism of estrogen action. Physiol.
Rev. 81, 1535-1565, 2001.
147. E. Enmark and J.-Å. Gustafsson: Comparing nuclear receptors in worms, flies and
humans. Trends Pharmacol. Sci., 22, 611-615, 2001.
148. Y. Zhu, Z. Bian, P. Lu, R. H. Karas, L. Bao, D. Cox, J. Hodgin, P. W. Shaul, P. Thorén, O.
Smithies, J.-Å. Gustafsson, M. E. Mendelsohn: Abnormal vascular function and
hypertension in mice deficient in estrogen receptor . Science, 295, 505-508, 2002.
149. C. Palmieri, G. J. Cheng, S. Saji, M. Zelada-Hedman, A. Wärri, Z. Weihua, S. Van
Noorden, T. Wahlstrom, R. C. Coombes, M. Warner, and J.-Å. Gustafsson: Estrogen
receptor beta in breast cancer. Endocrine-Related Cancer, 9, 1-13, 2002.
150. E.F. Rissman, A. L. Heck, J. E. Leonard, M. A. Shupnik, and J.-Å. Gustafsson: Disruption
of estrogen receptor  gene impairs spatial learning in female mice. Proc.Natl.Acad.Sci.
USA, 99, 3996-4001, 2002.
151. K. A. Risan Tobin, S. M. Ulven, G. U. Schuster, H. Hermansen Steineger, S. M. Andresen,
J.-Å. Gustafsson, and H. I. Nebb: Liver X receptors as insuling-mediating factors in fatty
acid and cholesterol biosynthesis. J. Biol. Chem., 277, 10691-10697, 2002.
152. A. Båvner, L. Johansson, G. Toresson, J.-Å. Gustafsson, E. Treuter: A transcriptional
inhibitor targeted by the atypical orphan nuclear receptor SHP. EMBO reports, 5, 478-484,
2002.
153. L. Wang, S. Andersson, M. Warner and J.-Å. Gustafsson: Estrogen actions in the brain.
Science STKE, 138, 2002.
http://stke.sciencemag.org/cgi/content/full/sigtrans;2002/138/pe29
154. T. M. Stulnig, U. Opperman, K. R. Steffensen, G. U. Schuster and J.-Å. Gustafsson: Liver
X receptor downregulates 11-hydroxysteroid dehydrogenase type 1 expression and
activity. Diabetes, 51, 2426-2433, 2002.
155. G. U. Schuster, P. Parini, L. Wang, S. Alberti, K. R. Steffensen, G. K. Hansson, B. Angelin,
J.-Å. Gustafsson: Accumulation of foam cells in liver X receptor-deficient mice.
Circulation, 106, 1147-1153, 2002.
156. L. Wang, G. U. Schuster, K. Hultenby, Q. Zhang, S. Andersson, and J.-Å. Gustafsson:
Liver X receptors in the central nervous system: From lipid homeostasis to neuronal
degeneration. Proc.Natl.Acad.Sci. USA, 99, 13878-13883, 2002.
157. Z. Weihua, R. Lathe, M. Warner, and J.-Å. Gustafsson: An endocrine pathway in the
prostate, ER, AR, 5-androstane-3, 17-diol, and CYP7B1, regulates prostate growth.
Proc.Natl.Acad.Sci. USA, 99, 13589-13594, 2002.
158. T. M. Stulnig, K.R. Steffensen, H. Gao, M. Reimers, K. Dahlman-Wright, G. U. Schuster,
and J.-Å. Gustafsson: Novel roles of liver X receptors exposed by gene expression
profiling in liver and adipose tissue. Mol. Pharmacol., 62, 1299-1305, 2002.
62
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
159. C. Förster, S. Mäkelä, A. Wärri, S. Kietz, D. Becker, K. Hultenby, M. Warner, and J.-Å.
Gustafsson: Involvement of estrogen receptor  in terminal differentiation of mammary
gland epithelium. Proc. Natl. Acad. Sci. USA, 99, 15578-15583, 2002.

160. S. H. Windahl, G. Andersson, and J.-Å. Gustafsson: Elucidation of estrogen receptor
function in bone with the use of mouse models. Trends Endocrin. Met., 13, 195-200, 2002.
161. S. Nilsson and J.-Å. Gustafsson: Biological role of estrogen and estrogen receptors.
Critical Rev. Biochem. Mol. Biol., 37, 1-28, 2002.
162. L. Wang, S. Andersson, M. Warner, and J.-Å. Gustafsson: Estrogen receptor (ER)
knockout mice reveal a role for ER in migration of corticol neurons in the developing
brain. Proc. Natl. Acad. Sci. USA, 100, 703-708, 2003.
163. M. K. Lindberg, S. Movérare, S. Skrtic, H. Gao, K. Dahlman-Wright, J.-Å. Gustafsson,
and C. Ohlsson: Estrogen receptor (ER)- reduces ER-regulated gene transcription,
supporting a “ying yang” relationship between ER and ER in mice. Mol. Endocrinol. 17,
203-208, 2003.
164. G.J. Shim, L. Wang, S. Andersson, N. Nagy, L. Levente Kis, Q. Zhang, S. Mäkelä, M.
Warner and J.-Å. Gustafsson: Disruption of the estrogen receptor beta gene in mice
causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid
blast crisis. Proc. Natl. Acad. Sci. USA., 100, 6694-6699, 2003.
165. M. Färnegårdh, T. Bonn, S. Sun, J. Ljunggren, H. Ahola, A. Wilhelmsson, J.-Å.
Gustafsson, and M. Carlquist: The three-dimensional structure of the liver X receptor 
reveals a flexible ligand-binding pocket that can accommodate fundamentally different
ligands. J. Biol. Chem., 278, 38821-38828, 2003.
166. C. Patrone, T. N. Cassel, K. Pettersson, Y.-S. Piao, G. Cheng, P. Ciana, A. Maggi, M.
Warner, J.-Å. Gustafsson, and M. Nord: Regulation of postnatal lung development and
homeostasis by estrogen receptor . Mol. Cell. Biol., 23, 8542-8552, 2003.
167. K. T. Dalen, S. M. Ulven, K. Bamberg, J.-Å. Gustafsson, and H. I. Nebb: Expression of
the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X
receptor . J. Biol. Chem., 278, 48283-48291, 2003.
168. C. Zhao, E. W.-F. Lam, A. Sunters, E. Enmark, M. Tamburo De Bella, R.C. Coombes, J.Å. Gustafsson, and K. Dahlman-Wright: Expression of estrogen receptor  isoforms in
normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene, 22,
7600-7606, 2003.
169. J.-Å. Gustafsson: What pharmacologists can learn from recent advances in estrogen
signaling. Trends Pharmacol. Sci., 2003.
170. M. Nilsson, S. Naessén, I. Dahlman, A. Lindén Hirschberg, J.-Å. Gustafsson and K.
Dahlman-Wright: Association of estrogen receptor  gene polymorphisms with bulimic
disease in women. Mol. Psychiatry, 9, 28-34, 2004.
63
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
171. A. Ström, J. Hartman, J.S. Foster, S. Kietz, J. Wimalasena, and J.-Å. Gustafsson:
Estrogen receptor  inhibits 17-estradiol-stimulated proliferation of the breast cancer cell
line T47D. Proc. Natl. Acad. Sci. USA, 101, 1566-1571, 2004.
172. G.-J. Shim, L. Levente Kis, M. Warner, and J.-Å. Gustafsson. Autoimmune
glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking
the estrogen receptor alpha gene. Proc. Natl. Acad. Sci. USA, 101, 1720-1724, 2004.
173. G. Cheng, Z. Weihua, M. Warner, and J.-Å. Gustafsson: Estrogen receptors ER and
ER in proliferation in the rodent mammary gland. Proc. Natl. Acad. Sci. USA, 101, 37393746, 2004.
174. N. Heldring, M. Nilsson, B. Buehrer, E. Treuter, and J.-Å. Gustafsson: Identification of
tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of
estrogen receptors. Mol. Cell Biol., 24, 3445-3459, 2004.
175. C. Palmieri, E. W.-F. Lam, J. Mansi, C. MacDonald, S. Shousha, P. Madden, Y. Omoto, A.
Sunters, M. Warner, J.-Å. Gustafsson and R.C. Coombes: The expression of ERcx in
human breast cancer and the relationship to endocrine therapy and survival. Clin. Cancer
Res., 10, 2421-2428, 2004.
176. O. Imamov, A. Morani, G.-J. Shim, Y. Omoto, C. Thulin-Andersson, M. Warner, and J.-Å.
Gustafsson: Estrogen receptor regulates epithelial cellular differentiation in the mouse
ventral prostate. Proc. Natl. Acad. Sci. USA., 101, 9375-9380, 2004.
177. G.-J. Shim, M. Warner, H.-J. Kim, S. Andersson, L. Liu, J. Ekman, O. Imamov, M. E.
Jones, E. R. Simpson, and J.-Å. Gustafsson: Aromatase-deficient mice spontaneously
develop a lymphoproliferative autoimmune disease resembling Sjögren’s syndrome. Proc.
Natl. Acad. Sci. USA., 101, 12628-12633, 2004.
178. M. Esslimani-Sahla, J. Simony-Lafontaine, A. Kramar, R. Lavaill, C. Mollevi, M. Warner,
J.-Å. Gustafsson, and H. Rochefort: Estrogen receptor  (ER) level but not its ERcx
variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res., 10, 57695776, 2004.
179. C. Förster, S. Kietz, K. Hultenby, M. Warner, and J.-Å. Gustafsson: Characterization of
the ER -/- mouse heart. Proc. Natl. Acad. Sci. USA., 101, 14234-14239, 2004.
180. J. Hartman, P. Müller, J. S. Foster, J. Wimalasena, J.-Å. Gustafsson, and A. Ström: HES1 inhibits 17-estradiol and heregulin-1-mediated upregulation of E2F-1. Oncogene, 23,
8826-8833, 2004.
181. O. Imamov, N. A. Lopatkin, J.-Å. Gustafsson: Estrogen receptor beta in prostate cancer.
N. Engl. J. Med., 351, 2773-2774, 2004.
182. K. Steffensen and J.-Å. Gustafsson: Putative metabolic effects of the liver X receptor
(LXR). Diabetes, 53, S36-S42, 2004.
183. H. Gronemeyer, J.-Å. Gustafsson, and V. Laudet: Principles for modulation of the
nuclear receptor superfamily. Nature Reviews Drug Discovery, 3, 950-964, 2004.
64
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
184. Y. Omoto, O. Imamov, M. Warner, and J.-Å. Gustafsson: Estrogen receptor  and
imprinting of the neonatal mouse ventral prostate by estrogen. Proc. Natl. Acad. Sci. USA.,
102, 1484-1489, 2005.
185. Y. Omoto, R. Lathe, M. Warner, and J.-Å. Gustafsson: Early onset of puberty and ovarian
failure in CYP7B1 knockout mice. Proc. Natl. Acad. Sci. USA., 102, 2814-2819, 2005.
186. S. Andersson, N. Gustafsson, M. Warner, and J.-Å. Gustafsson: Inactivation of liver X
receptor  leads to adult-onset motor neuron degeneration in male mice. Proc. Natl. Acad.
Sci. USA., 102, 3857-3862, 2005.
187. A.E. Kudwa, C. Bodo, J.-Å. Gustafsson, and E. F. Rissman: A previously uncharacterized
role for estrogen receptor : Defeminization of male brain and behavior. Proc. Natl. Acad.
Sci. USA., 102, 4608-4612, 2005.
188. M. Esslimani-Sahla, A. Kramar, J. Simony-Lafontaine, M. Warner, J.-Å. Gustafsson, and
H. Rochefort: Increased estrogen receptor cx expression during mammary
carcinogenesis. Clin. Cancer Res., 11, 3170-3174, 2005.
189. K. M. Robertson, G. U. Schuster, K. R. Steffensen, O. Hovatta, S. Meaney, K. Hultenby, L.
C. Johansson, K. Svechnikov, O. Söder, and J.-Å. Gustafsson: The liver X receptor- is
essential for maintaining cholesterol homeostasis in the testis. Endocrinology, 146, 25192530, 2005.
190. F. Morello, R. A. de Boer, K. R. Steffensen, M. Gnecchi, J. W. Chisholm, F. Boomsma, L.
M. Anderson, R. M. Lawn, J.-Å. Gustafsson, M. Lopez-Ilasaca, R. E. Pratt, and V. J.
Dzau: Liver X receptors  and  regulate renin expression in vivo, J. Clin. Invest. 115,
1913-1922, 2005.
191. A. Båvner, J. Matthews, S. Sanyal, J.-Å. Gustafsson and E. Treuter: EID3 is a novel EID
family member and an inhibitor of CBP-dependent co-activation. Nucleic Acids Res., 33,
3561-3569, 2005.
192. K. F. Koehler, L. A. Helguero, L.-A. Haldosén, M. Warner, and J.-Å. Gustafsson:
Reflections on the discovery and significance of estrogen receptor . Endocrine Rev., 29,
465-478, 2005.
193. J.-Å. Gustafsson: Steroids and the scientist. Mol. Endocrinol., 19, 1412-1417, 2005.
194. A. Båvner, S. Sanyal, J.-Å. Gustafsson and E. Treuter: Transcriptional corepression by
SHP: molecular mechanisms and physiological consequences. Trends Endocrin. Met, 16,
478-488, 2005.
195. R. P. A. Barros, U. F. Machado, M. Warner, and J.-Å. Gustafsson: Muscle GLUT4
regulation by estrogen receptors ER and ER. Proc. Natl. Acad. Sci. USA., 103, 16051608, 2006.
65
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
196. O. Wada-Hiraike, O. Imamov, H. Hiraike, K. Hultenby, T. Schwend, Y. Omoto, M. Warner,
and J.-Å. Gustafsson: Role of estrogen receptor  in colonic epithelium. Proc. Natl.
Acad. Sci. USA., 103, 2959-2964, 2006.
197. J. Matthews, B. Wihlén, M. Tujague, J. Wan, A. Ström, and J.-Å. Gustafsson: Estrogen
receptor (ER)  modulates ER-mediated transcriptional activation by altering the
recruitment of c-Fos and c-Jun to estrogen responsive promoters. Mol. Endo., 20, 534543, 2006.
198. C. Thellenberg-Karlsson, S. Lindström, B. Malmer, F. Wiklund, K. Augustsson-Bälter, H.O. Adami, P. Stattin, M. Nilsson, K. Dahlman-Wright, J.-Å. Gustafsson, and H. Grönberg:
Estrogen receptor  polymorphism is associated with prostate cancer risk. Clin. Cancer
Res., 12, 1936-1941, 2006.
199. A. Morani, R. P. A. Barros, O. Imamov, K. Hultenby, A. Arner, M. Warner, and J.-Å.
Gustafsson: Lung dysfunction causes systemic hypoxia in estrogen receptor knockout
(ER -/-) mice. Proc. Natl. Acad. Sci. USA., 103, 7165-7169, 2006.
200. H. Gao, G. Bryzgalova, E. Hedman, A. Khan, S. Efendic, J.-Å. Gustafsson, and K.
Dahlman-Wright: Long-term administration of estradiol decreases expression of hepatic
lipogenic genes and improves insulin sensitivity in ob/ob mice: A possible mechanism is
through direct regulation of signal transducer and activator of transcription 3. Mol.
Endocrinol., 6, 1287-1299, 2006.
201. K. M. Robertson, M. Norgård, S. H. Windahl, K. Hultenby, C. Ohlsson, G. Andersson, and
J.-Å. Gustafsson: Cholesterol-sensing receptors, liver X receptor and , have novel and
distinct roles in osteoclast differentiation and activation. J. Bone Min. Res., 21, 1276-1287,
2006.
202. O. Wada-Hiraike, H. Hiraike, H. Okinaga, O. Imamov, R. P. A. Barros, A. Morani, Y.
Omoto, M. Warner and J.-Å. Gustafsson: Role of estrogen receptor in uterine stroma
and epithelium: Insights from estrogen receptor mice. Proc. Natl. Acad. Sci. USA., 103,
18350-18355, 2006.
203. J. Hartman, K. Lindberg, A. Morani, J. Inzunza, A. Ström, and J.-Å. Gustafsson: Estrogen
receptor  inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer
Res., 23, 11207-11213, 2006.
204. X. Fan, M. Warner, and J.-Å. Gustafsson: Estrogen receptor  expression in the
embryonic brain regulates development of calretinin-immunoreactive GABAergic
interneurons. Proc. Natl. Acad. Sci. USA., 103, 19338-19343, 2006.
205. R. P. A. Barros, U. F. Machado, and J.-Å. Gustafsson: Estrogen receptors: new players
in diabetes mellitus. Trends Mol. Med., 12, 425-431, 2006.
206. U. Ohnemus, M. Uenalan, J. Inzunza, J.-Å. Gustafsson and R. Paus: The hair follicle as
an estrogen target and source. Endocrine Rev., 6, 677-706, 2006.
66
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
207. J. Inzunza, A. Morani, G. Cheng, M. Warner, J. Hreinsson, J.-Å. Gustafsson, and O.
Hovatta: Ovarian wedge resection restores fertility in estrogen receptor  knockout (ER-/-)
mice. Proc. Natl. Acad. Sci. USA, 104, 600-605, 2007.
208. C. Zhao, J. Matthews, M. Tujague, J. Wan, A. Ström, G. Toresson, E. W-F. Lam, G.
Cheng, J.-Å. Gustafsson and K. Dahlman-Wright: Estrogen receptor 2 negatively
regulates the transactivation of estrogen receptor  in human breast cancer cells. Cancer
Res., 67, 3955-3962, 2007.
209. O. Imamov, K. Yakimchuk, A. Morani, T. Schwend, O. Wada-Hiraike, S. Razumov, M.
Warner and J.-Å. Gustafsson: Estrogen receptor deficient female mice develop a
bladder phenotype resembling human interstitial cystitis. Proc. Natl. Acad. Sci. USA, 104,
9806-9809, 2007.
210. X. Fan, H.-J. Kim, M. Warner, and J.-Å.Gustafsson: Estrogen receptor  is essential for
sprouting of nociceptive primary afferents and for morphogenesis and maintenance of the
dorsal horn interneurons. Proc. Natl. Acad. Sci. USA, 104, 13696-13701, 2007.
211. C.-Y. Lin, A. Ström, S. L. Kong, S. Kietz, J. S. Thomsen, J. B. S. Tee, V. B. Vega, L. D.
Miller, J. Smeds, J. Bergh, J.-Å. Gustafsson, and E. T. Liu: Inhibitory effects of estrogen
receptor beta on specific hormone-responsive gene expression and association with
disease outcome in primary breast cancer. Breast Cancer Res., 9:R25, 1-11, 2007.
212. S. Sanyal, A. Båvner, A. Haroniti, L.-M. Nilsson, T. Lundåsen, S. Rehnmark, M.
Robin
Witt, C.Einarsson, I. Talianidis, J.-Å. Gustafsson, E. Treuter: Involvement of corepressor
complex subunit GPS2 in transcriptional pathways governing human bile acid
biosynthesis. Proc. Natl. Acad. Sci. USA, 104, 15665-15670, 2007.
213. E.. Treuter, and J.-Å. Gustafsson: Wrestling rules in transrepression: As easy as SUMO1, -2, -3? Mol. Cell, 25, 178-180, 2007.
214. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A.
Ström, E. Treuter, M. Warner, and J.-Å. Gustafsson: Estrogen receptors: How do they
signal and what are their targets? Physiol. Rev., 87, 905-931, 2007.
215. H. Gao, S. Fält, A. Sandelin, J.-Å. Gustafsson, and K. Dahlman-Wright: Genome-wide
identification of estrogen receptor -binding sites in mouse liver. Mol. Endocrinol., 22, 1022, 2008.
216. H.-J. Kim, X. Fan, C. Gabbi, K. Yakimchuk, P. Parini, M. Warner, and J.-Å. Gustafsson:
Liver X receptor  (LXR): A link between -sitosterol and amyotrophic lateral sclerosisParkinson’s dementia. Proc. Natl. Acad. Sci. USA, 105, 2094-2099, 2008.
217. C. Williams, K. Edvardsson, S.A. Lewandowski, A. Ström and J.-Å. Gustafsson: A
genome-wide study of the repressive effects of estrogen receptor beta on estrogen
receptor alpha signaling in breast cancer cells. Oncogene, 27, 1019-1032, 2008.
218. Y. Liu, H. Gao, T. T. Marstrand, A. Ström, E. Valen, A. Sandelin, J.-Å. Gustafsson, and K.
Dahlman-Wright: The genome landscape of ERα- and ERβ-binding DNA regions. Proc.
Natl. Acad. Sci. USA, 105, 2604-2609, 2008.
67
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
219. I. Meltser, Y. Tahera, E. Simpson, M. Hultcrantz, K. Charitidi, J.-Å. Gustafsson, and B.
Canlon: Estrogen receptor β protects against acoustic trauma in mice. J. Clin.
Investigation, 118, 1563-1570, 2008.
220. A. Foryst-Ludwig, M. Clemenz, S. Hohmann, M. Hartge, C. Sprang, N. Frost, M. Krikov, S.
Bhanot, R. Barros, A. Morani, J.-Å. Gustafsson, T. Unger and U. Kintscher: Metabolic
actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with
PPARγ. PLoS Genetics, 4, 1-16, 2008.
221. X. Fan, H.-J. Kim, D. Bouton, M. Warner, and J.-Å. Gustafsson: Expression of liver X
receptor β is essential for formation of superficial cortical layers and migration of later-born
neurons. Proc. Natl. Acad. Sci. USA, 105, 13445-13450, 2008.
222. C. Gabbi, H.-J. Kim, K. Hultenby, D. Bouton, G. Toresson, M. Warner, and J.-Å.
Gustafsson: Pancreatic exocrine insufficiency in LXRβ-/- mice is associated with a
reduction in aquaporin-1 expression. Proc. Natl. Acad. Sci. USA, 105, 15052-15057, 2008.
223. H.-J. Kim, L. C. Andersson, D. Bouton, M. Warner, and J.-Å. Gustafsson: Stromal growth
and epithelial cell proliferation in ventral prostates of liver X receptor knockout mice. Proc.
Natl. Acad. Sci. USA, 106, 558-563, 2009.
224. N. Sugiyama, S. Andersson, R. Lathe, X. Fan, P. Alonso-Magdalena, T. Schwend, I.
Nalvarte, M. Warner and J.-Å. Gustafsson: Spatiotemporal dynamics of the expression of
estrogen receptors in the postnatal mouse brain. Mol. Psychiatry, 14, 223-232, 2009.
225. C. Gabbi, M. Warner and J.-Å. Gustafsson: Minireview: Liver X receptor : Emerging roles
in physiology and diseases. Mol. Endocrinol., 23, 129-136, 2009.
226. K. Ogasawara, H. Nogami, M. C. Tsuda, J.-Å. Gustafsson, K. S. Korach, S. Ogawa, T.
Harigaya, and S. Hisano: Hormonal regulation of prolactin cell development in the fetal
pituitary gland of the mouse. Endocrinology, 150, 1061-1068, 2009.
227. P. Alonso-Magdalena, C. Brössner, A. Reiner, G. Cheng, N. Sugiyama, M. Warner, and J.Å. Gustafsson: A role for epithelial-mesenchymal transition in the etiology of benign
prostatic hyperplasia. Proc. Natl. Acad. Sci. USA, Early Edition, 2009.
Top 10 publications
1.
Ö. Wrange and J.-Å. Gustafsson: Separation of the hormone- and DNA-binding sites of
the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253, 856-865,
1978.
FIRST DEMONSTRATION OF DOMAIN STRUCTURE OF A NUCLEAR RECEPTOR
2.
Ö. Wrange, J. Carlstedt-Duke and J.-Å. Gustafsson: Purification of the glucocorticoid
receptor from rat liver cytosol. J. Biol. Chem. 254, 9284-9290, 1979.
68
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
FIRST PURIFICATION OF A NUCLEAR RECEPTOR TO HOMOGENEITY
3.
F. Payvar, Ö. Wrange, J. Carlstedt-Duke, S. Okret, J.-Å. Gustafsson and K.R.
Yamamoto: Purified glucocorticoid receptors bind selectively in vitro to a cloned DNA
fragment whose transcription is regulated by glucocorticoids in vivo. Proc. Natl. Acad.
Sci. USA 78, 6628-6632, 1981.
FIRST DEMONSTRATION OF SPECIFIC BINDING OF A NUCLEAR RECEPTOR TO DNA
4.
R. Miesfeld, S. Okret, A.-C. Wikström, Ö. Wrange, J.-Å. Gustafsson and K. Yamamoto:
Characterization of a steroid receptor gene and mRNA in wild-type and mutant cells.
Nature 312, 779-781, 1984.
FIRST CLONING OF A NUCLEAR RECEPTOR cDNA
5.
T. Härd, E. Kellenbach, R. Boelens, B. A. Maler, K. Dahlman, L. P. Freedman, J.
Carlstedt-Duke, K. R. Yamamoto, J.-Å. Gustafsson, and R. Kaptein: Solution structure of
the glucocorticoid receptor DNA-binding domain. Science, 249, 157-160, 1990.
FIRST 3-D STRUCTURE OF A NUCLEAR RECEPTOR DOMAIN (THE DBD)
6.
M. Göttlicher, E. Widmark, Q. Li, and J.-Å. Gustafsson: Fatty acids activate a chimera of
the clofibric acid-activated receptor and the glucocorticoid receptor. Proc.Natl.Acad.Sci.
USA, 89, 4653-4657, 1992.
FIRST DESCRIBED ACTIVATORS OF AN ORPHAN NUCLEAR RECEPTOR (FATTY ACIDS
FOR PPARα)
7.
M. Teboul, E. Enmark, Q. Li, A.C. Wikström, M. Pelto-Huikko, and J.-Å. Gustafsson: OR1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid
receptor. Proc. Natl. Acad. Sci. USA, 92, 2096-2100, 1995.
DISCOVERY OF LXRβ
8.
G.G.J.M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-Å. Gustafsson: Cloning
of a novel estrogen receptor expressed in rat prostate and ovary. Proc.Natl.Acad.Sci.
USA, 93, 5925-5930, 1996.
DISCOVERY OF THE 2ND ESTROGEN RECEPTOR, ERβ, CAUSING A PARADIGM SHIFT IN
OUR UNDERSTANDING OF ESTROGEN SIGNALING
9.
A.M. Brzozowski, A.C.W. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engström, L.
Öhman, G.L. Greene, J.-Å. Gustafsson and M. Carlquist: Insights into the molecular
basis of agonism and antagonism in the oestrogen receptor as revealed by complexes
with 17β-oestradiol and raloxifene. Nature, 389, 753-758, 1997.
DISCOVERY OF THE MOLECULAR MECHANISM OF ANTAGONISM (HELIX 12
PERTURBATION) WITHIN NUCLEAR RECEPTORS
10.
Z. Weihua, S. Mäkelä, L. C. Andersson, S. Salmi, S. Saji, J. I. Webster, E. V. Jensen, S.
Nilsson, M. Warner, and J.-Å. Gustafsson: A role for estrogen receptor in the regulation
of growth of the ventral prostate. Proc.Natl.Acad.Sci. USA, 98, 6330-6335, 2001.
69
Jan-Åke Gustafsson, M.D., Ph.D.
Revised February 6, 2009
DISCOVERY OF THE REGULATORY ROLE OF ERβ IN THE GROWTH OF THE PROSTATE
70